<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem. Soc. Trans</journal-id><journal-id journal-id-type="hwp">ppbiost</journal-id><journal-id journal-id-type="publisher-id">BST</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29986938</article-id><article-id pub-id-type="pmc">6103456</article-id><article-id pub-id-type="publisher-id">BST-46-829</article-id><article-id pub-id-type="doi">10.1042/BST20180025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>27</subject><subject>23</subject><subject>48</subject><subject>47</subject><subject>5</subject></subj-group></article-categories><title-group><article-title>Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Briston</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Hicks</surname><given-names>Amy R.</given-names></name><xref ref-type="aff" rid="af1"/></contrib></contrib-group><aff id="af1">Neurology Innovation Centre, Hatfield Research Laboratories, Eisai Ltd, Hatfield, U.K.</aff><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Thomas Briston (<email>thomas_briston@eisai.net</email>)
</corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>9</day><month>7</month><year>2018</year></pub-date><volume>46</volume><issue>4</issue><fpage>829</fpage><lpage>842</lpage><history><date date-type="received"><day>5</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>10</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Author(s)</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution License 4.0 (CC BY-NC-ND)</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="BST-46-829.pdf"/><abstract><p>Neurodegenerative proteinopathies are a group of pathologically similar, progressive disorders of the nervous system, characterised by structural alterations within and toxic misfolding of susceptible proteins. Oligomerisation of A&#x003b2;, tau, &#x003b1;-synuclein and TDP-43 leads to a toxin gain- or loss-of-function contributing to the phenotype observed in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and frontotemporal dementia. Misfolded proteins can adversely affect mitochondria, and post-mitotic neurones are especially sensitive to metabolic dysfunction. Misfolded proteins impair mitochondrial dynamics (morphology and trafficking), preventing functional mitochondria reaching the synapse, the primary site of ATP utilisation. Furthermore, a direct association of misfolded proteins with mitochondria may precipitate or augment dysfunctional oxidative phosphorylation and mitochondrial quality control, causing redox dyshomeostasis observed in disease. As such, a significant interest lies in understanding mechanisms of mitochondrial toxicity in neurodegenerative disorders and in dissecting these mechanisms with a view of maintaining mitochondrial homeostasis in disease. Recent advances in understanding mitochondrially controlled cell death pathways and elucidating the mitochondrial permeability pore bioarchitecture are beginning to present new avenues to target neurodegeneration. Novel mitochondrial roles of deubiquitinating enzymes are coming to light and present an opportunity for a new class of proteins to target therapeutically with the aim of promoting mitophagy and the ubiquitin&#x02013;proteasome system. The brain is enormously metabolically active, placing a large emphasis on maintaining ATP supply. Therefore, identifying mechanisms to sustain mitochondrial function may represent a common intervention point across all proteinopathies.</p></abstract><kwd-group kwd-group-type="author"><kwd>amyloid</kwd><kwd>mitochondria</kwd><kwd>mitophagy</kwd><kwd>neurodegeneration</kwd><kwd>tau proteins</kwd><kwd>&#x003b1;-synuclein</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The energetic requirements of neuronal excitability, synaptic activity and plasticity are extensive and are almost exclusively fulfilled by mitochondrial oxidative phosphorylation (OXPHOS) [<xref rid="BST-46-829C1" ref-type="bibr">1</xref>]. Mitochondria are often trafficked long distances to meet spatiotemporal adenosine triphosphate (ATP) requirements and dynamic mechanisms determine mitochondrial localisation to best satisfy local demands of the neurone. It is also now clear that, during the lifetime of a neurone, mitochondria can become dysfunctional to the extent they cannot maintain a proton motive force sufficient for ATP generation. Cellular mechanisms engage to remove damaged mitochondria and replenish the mitochondrial pool. These cycles of mitochondrial fusion and fission can become defective in neurodegenerative disorders and consequent accumulation of damaged components within mitochondria can adversely affect mitochondrial function and cellular homeostasis.</p></sec><sec id="s2"><title>Mitochondrial dysfunction in neurodegenerative proteinopathies</title><p>Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are pathologically similar, progressive neurodegenerative proteinopathies [<xref rid="BST-46-829C2" ref-type="bibr">2</xref>] (<xref rid="BST-46-829F1" ref-type="fig">Figure 1</xref>). Proteinopathy refers to a disease-causing conformational change in a protein that normally has other roles in cell biology. Such proteins undergo pathogenic misfolding and oligomerisation into higher-order structures, revealing self-templating conformations, and have an ability to undergo prion-like spreading between cells, together resulting in toxin gain- or loss-of-function [<xref rid="BST-46-829C2" ref-type="bibr">2</xref>,<xref rid="BST-46-829C3" ref-type="bibr">3</xref>]. Misfolded proteins can adversely affect mitochondria, either through a direct association, damaging mitochondrial DNA, altering trafficking and dynamics, deregulating bioenergetics and quality control pathways or promoting mitochondria-dependent cell death pathways. Mitochondrial dysfunction as a cause or a consequence of neurodegenerative disease pathogenesis is still debated and a self-perpetuating feed-forward toxic cycle may exist (<xref rid="BST-46-829F2" ref-type="fig">Figure 2</xref>).
<fig id="BST-46-829F1" orientation="portrait" position="float"><label>Figure&#x000a0;1.</label><caption><title>Pathological overlap of proteinopathies in different neurodegenerative diseases.</title><p>Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; DLB, dementia with Lewy bodies; MSA, multiple systems atrophy; PD, Parkinson's disease; PDD, Parkinson's disease dementia; TDP-43, TAR DNA-binding protein 43; FUS, fused in sarcoma.</p></caption><graphic xlink:href="BST-46-829-g0001"/></fig>
<fig id="BST-46-829F2" orientation="portrait" position="float"><label>Figure&#x000a0;2.</label><caption><title>Reciprocal relationship between mitochondrial function and protein misfolding.</title><p>Mitochondrial function is adversely affected by toxic misfolded proteins. Additionally, mitochondrial function is necessary for correct protein folding and processing in neurodegenerative proteinopathies.</p></caption><graphic xlink:href="BST-46-829-g0002"/></fig></p><sec id="s2a"><title>Mitochondrial relationship with amyloid &#x003b2; and tau</title><p>AD is the most prevalent proteinopathy, characterised by accumulation of extracellular plaques containing amyloid &#x003b2; (A&#x003b2;) and intracellular tangles of tau. A&#x003b2; and tau both have detrimental effects on mitochondria [<xref rid="BST-46-829C4" ref-type="bibr">4</xref>]. Disruptions in mitochondrial DNA maintenance, protein import, electron transport chain (ETC) activity and redox balance are all consequences of A&#x003b2;-induced toxicity [<xref rid="BST-46-829C5" ref-type="bibr">5</xref>&#x02013;<xref rid="BST-46-829C12" ref-type="bibr">12</xref>] (<xref rid="BST-46-829F3" ref-type="fig">Figure 3</xref> and <xref rid="BST-46-829TB1" ref-type="table">Table 1</xref>). Mitochondrial localisation of A&#x003b2; peptide has been observed, albeit the exact sub-mitochondrial topology remains less well defined [<xref rid="BST-46-829C13" ref-type="bibr">13</xref>,<xref rid="BST-46-829C14" ref-type="bibr">14</xref>] and, indeed, A&#x003b2; may be produced at the mitochondrial-associated membrane (MAM) [<xref rid="BST-46-829C15" ref-type="bibr">15</xref>], linking mitochondrial&#x02013;ER contact sites, Ca<sup>2+</sup> handling and bioenergetics to A&#x003b2; toxicity.
<fig id="BST-46-829F3" orientation="portrait" position="float"><label>Figure&#x000a0;3.</label><caption><title>Mitochondrial toxicity of misfolded proteins.</title><p>Red outline depicts misfolded proteins and arrows indicate mitochondrial directed association or toxicity.</p></caption><graphic xlink:href="BST-46-829-g0003"/></fig>
<table-wrap id="BST-46-829TB1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><title>Mitochondrial relationship and toxicities with AD associated pathogenic proteins</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Pathogenic protein</th><th align="left" rowspan="1" colspan="1">Mitochondrial toxicity or association</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="8" colspan="1">Amyloid &#x003b2;</td><td rowspan="1" colspan="1"><italic>Mitochondrial association and protein import:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C6" ref-type="bibr">6</xref>,<xref rid="BST-46-829C13" ref-type="bibr">13</xref>&#x02013;<xref rid="BST-46-829C15" ref-type="bibr">15</xref>,<xref rid="BST-46-829C37" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localised to mitochondria</p></list-item><list-item><p>A&#x003b2; peptide import mediated through the TOMM complex</p></list-item><list-item><p>Disruption of mitochondrial precursor protein import</p></list-item><list-item><p>Interaction with VDAC1 in AD patients, APP and APP/PS1 mice</p></list-item><list-item><p>Interaction/co-localisation with OSCP subunit of F<sub>1</sub>F<sub>0</sub>-ATP synthase</p></list-item><list-item><p>Production at the MAM</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Mitochondrial DNA maintenance:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C5" ref-type="bibr">5</xref>,<xref rid="BST-46-829C11" ref-type="bibr">11</xref>,<xref rid="BST-46-829C12" ref-type="bibr">12</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Deregulation of mitochondrially encoded mRNA transcripts (reduced complex I and increased complexes III and IV)</p></list-item><list-item><p>Increased somatic mtDNA mutations in AD brain</p></list-item><list-item><p>Oxidative damage to mtDNA</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>ETC and bioenergetics:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C6" ref-type="bibr">6</xref>&#x02013;<xref rid="BST-46-829C10" ref-type="bibr">10</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Increased complex I content and decreased complex I activity in tripleAD mice at 12 months</p></list-item><list-item><p>Reduced cytochrome <italic>C</italic> oxidase activity (complex IV) in platelet mitochondria of AD patients and APP overexpressing cell models and mice</p></list-item><list-item><p>Reduced ATP, respiratory rate and inner membrane potential</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Oxidative stress and cell death pathways:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C4" ref-type="bibr">4</xref>,<xref rid="BST-46-829C6" ref-type="bibr">6</xref>,<xref rid="BST-46-829C8" ref-type="bibr">8</xref>,<xref rid="BST-46-829C38" ref-type="bibr">38</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Oxidative stress, H<sub>2</sub>O<sub>2</sub> production and lipid peroxidation in APP mice</p></list-item><list-item><p>Increased superoxide levels APP/PS2 mice and triple AD mice</p></list-item><list-item><p>Cytochrome <italic>C</italic>-mediated apoptosis</p></list-item><list-item><p>Increased inner membrane localised CypD in mAPP mice</p></list-item></list></td></tr><tr><td rowspan="6" colspan="1">Tau</td><td rowspan="1" colspan="1"><italic>Mitochondrial association and protein import:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C6" ref-type="bibr">6</xref>,<xref rid="BST-46-829C17" ref-type="bibr">17</xref>,<xref rid="BST-46-829C22" ref-type="bibr">22</xref>,<xref rid="BST-46-829C23" ref-type="bibr">23</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Phospho&#x02013;tau interaction with VDAC1 in AD patients and APP, APP/PS1 and triple AD transgenic mice</p></list-item><list-item><p>N-terminal tau fragment localisation to mitochondria in AD brain</p></list-item><list-item><p>N-terminal tau fragment accumulation in human mitochondria isolated from synaptosomes correlates with synaptic changes in AD</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Deregulated mitophagy:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C17" ref-type="bibr">17</xref>,<xref rid="BST-46-829C19" ref-type="bibr">19</xref>,<xref rid="BST-46-829C20" ref-type="bibr">20</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>N-terminal tau fragment-mediated net mitochondrial removal and increased mitophagy</p></list-item><list-item><p>N-terminal tau fragment-induced trafficking and/or recruitment of parkin and UCHL-1 to mitochondria</p></list-item><list-item><p>Increased COX-IV and TOMM20 protein and mtDNA (ratio of mt-Atp6/Rpl13) in AD brain</p></list-item><list-item><p>Increased mitochondrial membrane potential (decelerated mitophagy)</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Mitochondrial trafficking and dynamics:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C17" ref-type="bibr">17</xref>,<xref rid="BST-46-829C18" ref-type="bibr">18</xref>,<xref rid="BST-46-829C21" ref-type="bibr">21</xref>,<xref rid="BST-46-829C24" ref-type="bibr">24</xref>,<xref rid="BST-46-829C25" ref-type="bibr">25</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Hyperphosphorylated tau impaired mitochondrial trafficking</p></list-item><list-item><p>Mitochondrial dynamic and trafficking defects following tau overexpression in cultured cells or in <italic>in vivo</italic> models of tauopathy</p></list-item><list-item><p>N-terminal tau fragment-induced mitochondrial redistribution to soma</p></list-item><list-item><p>Mislocalisation of DRP1</p></list-item><list-item><p>Enhanced levels of OPA1 and mitofusins (mfn1/mfn2) following hTau overexpression</p></list-item><list-item><p>Reduced mfn2 ubiquitination in hTau models</p></list-item><list-item><p>N-terminal tau fragment-induced mitochondrial fragmentation and cristae remodelling</p></list-item></list></td></tr></tbody></table></table-wrap></p><p>Tau is a highly soluble, natively unfolded protein [<xref rid="BST-46-829C16" ref-type="bibr">16</xref>]. Tau hyperphosphorylation impairs its ability to bind and stabilise microtubules, and tau aggregation and intraneuronal filaments are common in the pathology of tauopathies (<xref rid="BST-46-829F1" ref-type="fig">Figure 1</xref>). The influence of tau on mitochondrial dynamics and quality control is well documented [<xref rid="BST-46-829C17" ref-type="bibr">17</xref>&#x02013;<xref rid="BST-46-829C21" ref-type="bibr">21</xref>] (<xref rid="BST-46-829F3" ref-type="fig">Figure 3</xref>). N-terminal tau fragments are associated with mitochondrial functional changes and defects in mitochondrial quality control, and the accumulation of tau fragments in human mitochondria isolated from synaptosomes correlates with synaptic changes observed in AD [<xref rid="BST-46-829C17" ref-type="bibr">17</xref>,<xref rid="BST-46-829C22" ref-type="bibr">22</xref>,<xref rid="BST-46-829C23" ref-type="bibr">23</xref>]. Changes in mitochondrial dynamics are also observed following tau overexpression in cultured cells or in <italic>in vivo</italic> models of tauopathy [<xref rid="BST-46-829C18" ref-type="bibr">18</xref>,<xref rid="BST-46-829C24" ref-type="bibr">24</xref>,<xref rid="BST-46-829C25" ref-type="bibr">25</xref>] (<xref rid="BST-46-829TB1" ref-type="table">Table 1</xref>).</p><p>Some literature suggests that the accumulation of (phospho-)tau and A&#x003b2; is a direct consequence of mitochondrial dysfunction [<xref rid="BST-46-829C26" ref-type="bibr">26</xref>&#x02013;<xref rid="BST-46-829C30" ref-type="bibr">30</xref>]. Perturbations to mitochondrial proteases and chaperones have demonstrated relationships with AD disease markers. Missense mutations in the mitochondrial matrix peptidase, pitrilysin metalloprotease 1 (PITRM1), are associated with A&#x003b2;-positive deposits and a slowly progressing neurodegenerative phenotype [<xref rid="BST-46-829C31" ref-type="bibr">31</xref>]. In addition, decreased activity in pre-sequence protease (PreP) has been observed in the temporal lobe region of AD patients [<xref rid="BST-46-829C32" ref-type="bibr">32</xref>] and has been linked to A&#x003b2; processing [<xref rid="BST-46-829C33" ref-type="bibr">33</xref>]. Overexpression of heat shock chaperone, mortalin, alleviates A&#x003b2;-induced toxicity, while pharmacological inhibition or siRNA down-regulation of mortalin induces DRP-1 (dynamin-related protein 1)-mediated mitochondrial fission and potentiates A&#x003b2;-induced mitochondrial and cellular toxicity [<xref rid="BST-46-829C34" ref-type="bibr">34</xref>,<xref rid="BST-46-829C35" ref-type="bibr">35</xref>]. With respect to pathogenic tau, antioxidant treatment of <italic>sod2</italic> nullizygous neonatal mice reverses phospho&#x02013;tau accumulation, placing mitochondrial oxidative stress upstream of tau pathology [<xref rid="BST-46-829C26" ref-type="bibr">26</xref>]. Finally, mitochondrial dysfunction induced by loss of either prohibitin 2 (PHB2), a mitochondrial membrane scaffold protein, or the <italic>m</italic>-AAA protease subunit, AFG3L2, both results in tau hyperphosphorylation [<xref rid="BST-46-829C27" ref-type="bibr">27</xref>,<xref rid="BST-46-829C36" ref-type="bibr">36</xref>], potentially linking mitochondrial dysfunction and the cytoskeleton. Taken together, these observations link mitochondrial dynamics, quality control and function to accumulation and toxicity of A&#x003b2; and tau.</p></sec><sec id="s2b"><title>Mitochondrial toxicity associated with synucleinopathies</title><p>PD is characterised by loss of dopaminergic neurones within the substantia nigra pars compacta and reduced dopamine innovation to the striatum. Mitochondrial dysfunction is a prominent pathological feature of both sporadic and familial diseases [<xref rid="BST-46-829C39" ref-type="bibr">39</xref>&#x02013;<xref rid="BST-46-829C45" ref-type="bibr">45</xref>], and many PD-causing genes have overt mitochondrial phenotypes [<xref rid="BST-46-829C44" ref-type="bibr">44</xref>&#x02013;<xref rid="BST-46-829C53" ref-type="bibr">53</xref>]. Accumulation of insoluble &#x003b1;-synuclein (&#x003b1;-syn) is a common feature of many clinical phenotypes, known collectively as synucleinopathies [<xref rid="BST-46-829C54" ref-type="bibr">54</xref>] (<xref rid="BST-46-829F1" ref-type="fig">Figure 1</xref>).</p><p>Mitochondrial localisation of &#x003b1;-syn negatively affects mitochondrial function, morphology and dynamics [<xref rid="BST-46-829C46" ref-type="bibr">46</xref>,<xref rid="BST-46-829C55" ref-type="bibr">55</xref>&#x02013;<xref rid="BST-46-829C60" ref-type="bibr">60</xref>] (<xref rid="BST-46-829F3" ref-type="fig">Figure 3</xref> and <xref rid="BST-46-829TB2" ref-type="table">Table 2</xref>). Constitutive import of &#x003b1;-syn to mitochondria is transmembrane potential-dependent and is facilitated through a cryptic mitochondrial targeting sequence within the N-terminal region [<xref rid="BST-46-829C57" ref-type="bibr">57</xref>]. &#x003b1;-Syn associates with the mitochondrial inner membrane where a direct interaction and toxicity towards mitochondrial complex I has been observed [<xref rid="BST-46-829C46" ref-type="bibr">46</xref>,<xref rid="BST-46-829C57" ref-type="bibr">57</xref>]. Oligomeric and dopamine-modified &#x003b1;-syn-dependent reduction in protein import occurs via disruption of the association between translocase of the outer mitochondrial membrane (TOMM)-20 and its co-receptor, TOMM22 [<xref rid="BST-46-829C61" ref-type="bibr">61</xref>]. As a result, diminished protein import in nigrostriatal neurones impairs mitochondrial function, decreasing respiration and transmembrane potential, and increasing mitochondrial reactive oxygen species (ROS) [<xref rid="BST-46-829C61" ref-type="bibr">61</xref>]. Purification of crude mitochondrial preparations has led to the hypothesis that &#x003b1;-syn is, in fact, localised to the MAM [<xref rid="BST-46-829C58" ref-type="bibr">58</xref>] and &#x003b1;-syn point mutations reduce mitochondria&#x02013;ER contacts, causing mitochondrial fragmentation [<xref rid="BST-46-829C58" ref-type="bibr">58</xref>]. Finally, &#x003b1;-syn has significant effects on mitochondrial quality control and its accumulation is becoming recognised as a consequence of deficient mitophagy [<xref rid="BST-46-829C50" ref-type="bibr">50</xref>,<xref rid="BST-46-829C62" ref-type="bibr">62</xref>,<xref rid="BST-46-829C63" ref-type="bibr">63</xref>]. &#x003b1;-Syn competes with LC3 for cardiolipin on the outer mitochondrial membrane. Cardiolipin facilitates refolding of &#x003b1;-syn oligomers; however, following prolonged exposure, LC3 is recruited. Mutated &#x003b1;-Syn is less able to compete with LC3, contributing to increased mitophagic flux observed in disease cells [<xref rid="BST-46-829C64" ref-type="bibr">64</xref>].
<table-wrap id="BST-46-829TB2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><title>Mitochondrial toxicities associated with synucleinopathies</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Pathogenic protein</th><th align="left" rowspan="1" colspan="1">Mitochondrial toxicity or association</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="10" colspan="1">&#x003b1;-Synuclein</td><td rowspan="1" colspan="1"><italic>Mitochondrial association and protein import:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C46" ref-type="bibr">46</xref>,<xref rid="BST-46-829C57" ref-type="bibr">57</xref>&#x02013;<xref rid="BST-46-829C59" ref-type="bibr">59</xref>,<xref rid="BST-46-829C61" ref-type="bibr">61</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Disruption of TOMM20 and co-receptor interaction leading to inhibition of mitochondrial protein import</p></list-item><list-item><p>Localised to MAM</p></list-item><list-item><p>Localised to mitochondria in striatum and substantia nigra of PD brain</p></list-item><list-item><p>A53T &#x003b1;-synuclein localised to the mitochondria as both monomers and oligomers</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Mitochondrial dynamics and morphology:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C58" ref-type="bibr">58</xref>&#x02013;<xref rid="BST-46-829C60" ref-type="bibr">60</xref>,<xref rid="BST-46-829C65" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x003b1;-Synuclein-induced mitochondrial fragmentation via effects on ER&#x02013;mitochondria contact sites</p></list-item><list-item><p>&#x003b1;-Synuclein-mediated destabilisation of the spectrin cytoskeleton and mislocalisation of DRP1</p></list-item><list-item><p>Mitochondrial fragmentation and disordered cristae following &#x003b1;-synuclein overexpression</p></list-item><list-item><p>Wild-type and A53T &#x003b1;-synuclein outer mitochondrial membrane localisation associated with mitochondrial fragmentation</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>ETC and bioenergetics:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C46" ref-type="bibr">46</xref>,<xref rid="BST-46-829C56" ref-type="bibr">56</xref>,<xref rid="BST-46-829C57" ref-type="bibr">57</xref>,<xref rid="BST-46-829C66" ref-type="bibr">66</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Monomeric and oligomeric A53T &#x003b1;-synuclein-induced complex I dysfunction in dopaminergic midbrain neurones</p></list-item><list-item><p>Reduced complex I activity in &#x003b1;-synuclein overexpressing cell lines and PD brain</p></list-item><list-item><p>Reduced complex IV activity in spinal neurones of A53T &#x003b1;-synuclein transgenic mice</p></list-item><list-item><p>Complex I misassembly in PD brains</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Deregulated mitophagy:</italic></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Enhanced mitophagy in mutant &#x003b1;-synuclein expressing cells following reduced cardiolipin-mediated refolding</p></list-item></list></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><italic>Oxidative stress and cell death pathways:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C55" ref-type="bibr">55</xref>,<xref rid="BST-46-829C57" ref-type="bibr">57</xref>,<xref rid="BST-46-829C66" ref-type="bibr">66</xref>,<xref rid="BST-46-829C67" ref-type="bibr">67</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>N-terminal &#x003b1;-synuclein regulation of mitochondrial membrane permeability</p></list-item><list-item><p>Association of &#x003b1;-synuclein with the ANT</p></list-item><list-item><p>Increased oxidative stress in &#x003b1;-synuclein overexpressing cell lines</p></list-item><list-item><p>Oxidation of complex I in frontal cortex of PD brain</p></list-item></list></td></tr></tbody></table></table-wrap></p></sec><sec id="s2c"><title>Mitochondrial toxicity in ALS and FTD-linked proteinopathies</title><p>ALS and FTD share pathological and genetic similarities and potentially common neurodegenerative pathways [<xref rid="BST-46-829C68" ref-type="bibr">68</xref>]. Aggregated transactive response DNA-binding protein 43&#x02005;kDa (TDP-43) and fused in sarcoma (FUS) are pathological hallmarks of both ALS and FTD (<xref rid="BST-46-829F1" ref-type="fig">Figure 1</xref>). Both are ribonuclear proteins and contain prion-like domains, rich in glycine molecules, increasing their propensity for aggregation and cell-to-cell transmission. Dysfunction in OXPHOS, Ca<sup>2+</sup> handling and ROS have all been proposed as key mitochondrially-associated determinants of ALS pathogenesis [<xref rid="BST-46-829C69" ref-type="bibr">69</xref>] (<xref rid="BST-46-829TB3" ref-type="table">Table 3</xref>). Furthermore, mitochondrial trafficking defects are responsible for accumulation of defective mitochondria around cell bodies in motor neurones [<xref rid="BST-46-829C69" ref-type="bibr">69</xref>].
<table-wrap id="BST-46-829TB3" orientation="portrait" position="float"><label>Table&#x000a0;3</label><caption><title>Mitochondrial toxicities for ALS/FTD associated pathogenic proteins</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Pathogenic protein</th><th align="left" rowspan="1" colspan="1">Mitochondrial toxicity or association</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="8" colspan="1">TDP-43</td><td rowspan="1" colspan="1"><italic>Mitochondrial association and protein import:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C74" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>N-terminal (27&#x02005;kDa) and C-terminal (30&#x02005;kDa) fragments of TDP-43 are localised to mitochondria in APP/PS1 mice</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Mitochondrial dynamics and morphology:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C73" ref-type="bibr">73</xref>,<xref rid="BST-46-829C75" ref-type="bibr">75</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduced mfn1 and increased fis1, correlating with increasing TDP-43 expression in brain lysates</p></list-item><list-item><p>Morphological and ultrastructural alterations observed in animal models of TDP-43 pathology</p></list-item><list-item><p>Mitochondrial fragmentation following mutant TDP-43 overexpression</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Mitochondrial trafficking:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C72" ref-type="bibr">72</xref>,<xref rid="BST-46-829C73" ref-type="bibr">73</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Mitochondria and organelle redistribution and clustering within cytoplasmic inclusions</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1"><italic>Deregulated mitophagy:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C74" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>TDP-43 knockdown decreases mitophagy</p></list-item></list></td></tr><tr><td rowspan="4" colspan="1">FUS</td><td rowspan="1" colspan="1"><italic>Mitochondrial dynamics and morphology:</italic></td><td rowspan="2" colspan="1">[<xref rid="BST-46-829C70" ref-type="bibr">70</xref>,<xref rid="BST-46-829C71" ref-type="bibr">71</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Disorganised ER and mitochondria within cytoplasmic inclusions of spinal motor neurones</p></list-item><list-item><p>Mitochondrial COX-IV-positive aggregates</p></list-item></list></td></tr></tbody></table></table-wrap></p><p>Ubiquitin-positive aggregates are observed in aged, mutant <italic>FUS-</italic>expressing transgenic animals and correlate with neuronal loss. Aggregates are also positive for mitochondrial cytochrome C oxidase (COX-IV), suggesting that defective mitochondria may be tagged for removal through the mitophagic machinery [<xref rid="BST-46-829C70" ref-type="bibr">70</xref>]. Similar pathology has been observed in a single post-mortem analysis of an <italic>FUS</italic> mutation carrier [<xref rid="BST-46-829C71" ref-type="bibr">71</xref>]. C- and N-terminal fragments of TDP-43 have been identified within mitochondria in Amyloid precursor protein (APP)/PS1 mice and mitochondrial dynamic changes, including trafficking and quality control defects, organelle redistribution and clustering within cytoplasmic inclusions, as well as morphological and ultrastructural alterations, are observed in animal models of TDP-43 pathology [<xref rid="BST-46-829C72" ref-type="bibr">72</xref>&#x02013;<xref rid="BST-46-829C74" ref-type="bibr">74</xref>]. Taken together, these observations suggest a phenotype of dysfunctional, mislocalised and fragmented mitochondria in ALS and FTD (<xref rid="BST-46-829F3" ref-type="fig">Figure 3</xref>).</p></sec></sec><sec id="s3"><title>Mitochondrially targeted strategies as disease-modifiers in neurodegenerative proteinopathies</title><p>Despite evidence of mitochondrial dysfunction in the pathology of proteinopathies and exacerbation of neurodegenerative disorders, the exact biochemical, neurotoxic mechanisms of misfolded, aggregated proteins remain poorly understood. Protecting mitochondrial function therefore may be one plausible drug discovery strategy for neuroprotective or disease-modifying end-points.</p><sec id="s3a"><title>Inhibition of mitochondrial permeability transition pore opening</title><p>Mitochondrial permeability transition pore (mPTP) opening has been implicated as a major cell death pathway in multiple neurodegenerative diseases [<xref rid="BST-46-829C76" ref-type="bibr">76</xref>&#x02013;<xref rid="BST-46-829C78" ref-type="bibr">78</xref>]. A shift in the mitochondrial redox balance towards oxidative stress, coupled with Ca<sup>2+</sup> overload, triggers opening of the mPTP leading to osmotic swelling, uncoupling of electron transport and metabolic collapse [<xref rid="BST-46-829C79" ref-type="bibr">79</xref>&#x02013;<xref rid="BST-46-829C86" ref-type="bibr">86</xref>]. The mitochondrial matrix enzyme, cyclophilin D (CypD), is a known positive regulator of mPTP opening [<xref rid="BST-46-829C86" ref-type="bibr">86</xref>]. Genetic ablation or pharmacological inhibition of CypD desensitises the pore to Ca<sup>2+</sup>, restricting pore opening [<xref rid="BST-46-829C85" ref-type="bibr">85</xref>,<xref rid="BST-46-829C86" ref-type="bibr">86</xref>]. Direct binding between A&#x003b2; and CypD links amyloid toxicity to mPTP opening in AD [<xref rid="BST-46-829C38" ref-type="bibr">38</xref>,<xref rid="BST-46-829C87" ref-type="bibr">87</xref>] and CypD deficiency corrects mitochondrial trafficking defects observed in AD models [<xref rid="BST-46-829C88" ref-type="bibr">88</xref>]. Previous literature supports a role for the F<sub>1</sub>F<sub>0</sub>-ATP synthase in pore formation [<xref rid="BST-46-829C89" ref-type="bibr">89</xref>,<xref rid="BST-46-829C90" ref-type="bibr">90</xref>], suggesting that the oligomycin-sensitivity conferring protein (OSCP) serves as a docking site for CypD [<xref rid="BST-46-829C90" ref-type="bibr">90</xref>]. Interestingly, OSCP is decreased during AD progression and may directly interact with A&#x003b2; [<xref rid="BST-46-829C37" ref-type="bibr">37</xref>]. Given the relationship between CypD, OSCP, A&#x003b2; and the propensity for mPTP opening, it is plausible that targeting these processes may have clinical benefits. Indeed, recently, phenotypic screening approaches have identified mPTP inhibitors and CypD-binding compounds in a model of A&#x003b2;-induced mPTP opening [<xref rid="BST-46-829C91" ref-type="bibr">91</xref>&#x02013;<xref rid="BST-46-829C94" ref-type="bibr">94</xref>]. Overexpression of an N-terminal region of &#x003b1;-syn has also been observed to regulate mitochondrial membrane permeability [<xref rid="BST-46-829C67" ref-type="bibr">67</xref>], linking mPTP to synucleinopathies. Moreover, following overexpression, &#x003b1;-syn associates with the adenine nucleotide translocase (ANT), another putative pore component [<xref rid="BST-46-829C95" ref-type="bibr">95</xref>,<xref rid="BST-46-829C96" ref-type="bibr">96</xref>]. Interestingly, pharmacological inhibition of ANT partially reverses the associated &#x003b1;-syn-induced mitochondrial toxicity [<xref rid="BST-46-829C97" ref-type="bibr">97</xref>].</p><p>Homology within the cyclophilin isoenzyme family makes selective targeting of CypD therapeutically challenging [<xref rid="BST-46-829C98" ref-type="bibr">98</xref>]. Moreover, since CypD does not constitute a principal pore component, and effects are indirect, mitochondria remain capable of permeability transition given enough stimuli [<xref rid="BST-46-829C86" ref-type="bibr">86</xref>,<xref rid="BST-46-829C99" ref-type="bibr">99</xref>]. CypD confers sensitivity to the mPTP inhibitor, cyclosporin A (CsA) [<xref rid="BST-46-829C85" ref-type="bibr">85</xref>,<xref rid="BST-46-829C100" ref-type="bibr">100</xref>], and number of CsA analogues have been developed [<xref rid="BST-46-829C101" ref-type="bibr">101</xref>,<xref rid="BST-46-829C102" ref-type="bibr">102</xref>]. CsA and its derivatives are large molecular mass natural products and penetrate the blood&#x02013;brain barrier poorly, limiting efficacy in neurodegenerative disease. Many groups have developed CypD-independent inhibitors [<xref rid="BST-46-829C103" ref-type="bibr">103</xref>&#x02013;<xref rid="BST-46-829C107" ref-type="bibr">107</xref>], but to date, none, as far as we are aware, have been tested in models of neurodegenerative disease.</p></sec><sec id="s3b"><title>Activating mitophagy to improve mitochondrial function in neurodegenerative proteinopathies</title><p>Dysfunctional lysosomal and proteasomal degradation pathways have been implicated in neurodegenerative diseases. A selective form of macroautophagy, termed mitophagy, is responsible for the clearance of defective mitochondria from cells [<xref rid="BST-46-829C44" ref-type="bibr">44</xref>,<xref rid="BST-46-829C45" ref-type="bibr">45</xref>,<xref rid="BST-46-829C108" ref-type="bibr">108</xref>&#x02013;<xref rid="BST-46-829C110" ref-type="bibr">110</xref>]. PTEN-induced putative kinase 1 (PINK1) and parkin are regulators of mitophagy and are integral to a mechanism that identifies and tags defective mitochondria for removal [<xref rid="BST-46-829C110" ref-type="bibr">110</xref>,<xref rid="BST-46-829C111" ref-type="bibr">111</xref>] (<xref rid="BST-46-829F4" ref-type="fig">Figure 4</xref>). The association between mutations in these proteins and dysfunction in the mitophagy pathway has direct implications in both familial and sporadic PD [<xref rid="BST-46-829C43" ref-type="bibr">43</xref>,<xref rid="BST-46-829C51" ref-type="bibr">51</xref>,<xref rid="BST-46-829C112" ref-type="bibr">112</xref>].
<fig id="BST-46-829F4" orientation="portrait" position="float"><label>Figure&#x000a0;4.</label><caption><title>Defective mitochondria are removed from the cell by mitophagy.</title><p>In healthy mitochondria, mitophagy proceeds at a slow rate due to the low abundance of ubiquitinated mitochondrial proteins, PINK1 import and degradation. PINK1 is stabilised on the OMM following mitochondrial depolarisation and phosphorylates both parkin and ubiquitin. Parkin is activated and translocates to mitochondria. Parkin ubiquitinates outer membrane proteins which then serve as targets for autophagic adaptor proteins and mitochondria are then cleared through the autophagic machinery. Abbreviations: IMM, inner mitochondrial membrane; OMM, outer mitochondrial membrane; TIMM, translocase of the inner mitochondrial membrane; MPP, mitochondrial processing peptidase; MTS, mitochondrial targeting sequence; TOMM, translocase of the outer mitochondrial membrane; Ub, ubiquitin.</p></caption><graphic xlink:href="BST-46-829-g0004"/></fig></p><p>PINK1 and parkin function may be necessary for &#x003b1;-syn clearance. Preceding neurodegeneration, &#x003b1;-syn A53T transgenic mice accumulate neuronal inclusions containing mitochondrial remnants and autophagic markers which increase in size and number with PINK1 or parkin knockout [<xref rid="BST-46-829C62" ref-type="bibr">62</xref>]. PINK1 loss-of-function potentiates the A53T phenotype, decreasing lifespan and enhancing movement deficits and protein aggregation [<xref rid="BST-46-829C63" ref-type="bibr">63</xref>]. Similarly, iPSCs from mutant PINK1/parkin carriers accumulate cytoplasmic inclusions and insoluble &#x003b1;-syn, a phenotype which can be partially corrected following PINK1 re-expression [<xref rid="BST-46-829C50" ref-type="bibr">50</xref>]. Interestingly, following mitochondrial uncoupling, autophagic &#x003b1;-syn removal is reduced and the likelihood of aggregate formation in oligodendrocytes is enhanced, suggesting that mitochondrial damage over time may play a role in &#x003b1;-syn accumulation [<xref rid="BST-46-829C48" ref-type="bibr">48</xref>]. Finally, a novel mechanism of PINK1 protection in &#x003b1;-syn models has been proposed as being mediated through protein phosphatase 2A activity [<xref rid="BST-46-829C113" ref-type="bibr">113</xref>].</p><p>Mitophagy has been linked to both A&#x003b2; and tau in AD. PINK1 is down-regulated in AD patients and in transgenic AD models [<xref rid="BST-46-829C114" ref-type="bibr">114</xref>]. Furthermore, the absence of PINK1 augments the mutant APP phenotype and stereotaxic injection of rAAV2&#x02013;PINK1 into the hippocampus of mutant APP mice signi&#x0fb01;cantly reduced A&#x003b2; compared with control, improving synaptic function and memory [<xref rid="BST-46-829C114" ref-type="bibr">114</xref>]. An association between deficient mitophagy and abnormal tau accumulation has been found in AD patient brain homogenate and transgenic mice. This deficit can be rescued by up-regulating parkin expression [<xref rid="BST-46-829C20" ref-type="bibr">20</xref>]. Exogenous parkin has also been found to decrease A&#x003b2; levels <italic>in vitro</italic> and A&#x003b2;-induced plaque formation in transgenic mice [<xref rid="BST-46-829C115" ref-type="bibr">115</xref>&#x02013;<xref rid="BST-46-829C117" ref-type="bibr">117</xref>].</p><p>Parkin activation may be a promising strategy to enhance mitophagy in disease models. Nilotinib, originally discovered as a tyrosine kinase inhibitor, increases parkin abundance and ubiquitination, potentially increasing parkin recycling via the proteasome [<xref rid="BST-46-829C118" ref-type="bibr">118</xref>]. Nilotinib-mediated c-ABL inhibition also prevents parkin tyrosine phosphorylation, resulting in release of parkin auto-inhibition and demonstrating protection in PD models [<xref rid="BST-46-829C119" ref-type="bibr">119</xref>]. Additionally, nilotinib has been demonstrated to increase the parkin&#x02013;beclin 1 interaction and increase clearance of A&#x003b2; in transgenic APP mice following chronic treatment [<xref rid="BST-46-829C120" ref-type="bibr">120</xref>]. Finally, with respect to ALS and FTD, motor and cognitive deficits measured in TDP-43 transgenic mice have also been reversed using nilotinib [<xref rid="BST-46-829C121" ref-type="bibr">121</xref>].</p></sec><sec id="s3c"><title>Deubiquitinating (deubiquitinase; DUB) enzymes in neurodegenerative proteinopathies</title><p>Down-regulation of the ubiquitin&#x02013;proteasome system (UPS) is common across neurodegenerative diseases and promoting UPS activity is an emerging strategy for the treatment of proteinopathies. Deubiquitinases (DUBs) hydrolyse isopeptide bonds covalently binding ubiquitin to proteins, regulating degradation, localisation or activity. Multiple DUBs regulate mitochondrial function [<xref rid="BST-46-829C122" ref-type="bibr">122</xref>&#x02013;<xref rid="BST-46-829C126" ref-type="bibr">126</xref>]. Ubiquitin-specific protease 15 (USP15) and USP30 both antagonise parkin-mediated mitophagy [<xref rid="BST-46-829C122" ref-type="bibr">122</xref>,<xref rid="BST-46-829C125" ref-type="bibr">125</xref>]. USP30 is the only DUB exclusively localised to mitochondria [<xref rid="BST-46-829C127" ref-type="bibr">127</xref>], tethered to the outer mitochondrial membrane. USP30 deubiquitinates parkin substrates, including TOMM20 and MIRO1 [<xref rid="BST-46-829C122" ref-type="bibr">122</xref>], and inhibition has been proposed to enhance parkin-mediated mitophagy [<xref rid="BST-46-829C128" ref-type="bibr">128</xref>,<xref rid="BST-46-829C129" ref-type="bibr">129</xref>] (<xref rid="BST-46-829F4" ref-type="fig">Figure 4</xref>). In one study, USP35 was also found to oppose parkin-mediated mitophagy, with both a distinct mechanism to USP30 and lack of influence on the translocation of parkin [<xref rid="BST-46-829C124" ref-type="bibr">124</xref>]. USP8 enhances mitophagy by removing lysine-6-linked ubiquitin from parkin, promoting its turnover [<xref rid="BST-46-829C126" ref-type="bibr">126</xref>]. However, confusingly, USP8 knockout also limits toxicity in an &#x003b1;-syn model in <italic>Drosophila melanogaster</italic> [<xref rid="BST-46-829C130" ref-type="bibr">130</xref>]. Other DUBs localise to mitochondria, albeit not exclusively; Ataxin-3 [<xref rid="BST-46-829C131" ref-type="bibr">131</xref>,<xref rid="BST-46-829C132" ref-type="bibr">132</xref>] and the X-chromosome-linked deubiquitinase, USP9x [<xref rid="BST-46-829C132" ref-type="bibr">132</xref>] have demonstrated mitochondrial localisation under specific conditions. USP9x deubiquitinates &#x003b1;-syn and silencing increases the abundance of mono-ubiquitinated &#x003b1;-syn, enhancing its propensity for aggregation [<xref rid="BST-46-829C133" ref-type="bibr">133</xref>].</p></sec><sec id="s3d"><title>Eliminating ROS in neurodegenerative proteinopathies</title><p>Mitochondria are a principal source of cellular ROS. ROS are generated as a by-product of OXPHOS and their abundance presents a fine balance between signalling and toxicity. Much interest has focussed around limiting oxidative stress in neurodegenerative disease. Exogenous expression of a mitochondrially targeted catalase decreases monomeric and oligomeric A&#x003b2; and A&#x003b2; plaques in mice carrying the APP KM670/671NL (Swedish) mutation [<xref rid="BST-46-829C134" ref-type="bibr">134</xref>]. Synthetic analogues of mitochondrial coenzyme Q<sub>10</sub> prevent A&#x003b2; oligomer-induced changes in mitochondrial mRNA transcript expression, protecting cells against oligomeric A&#x003b2; damage [<xref rid="BST-46-829C135" ref-type="bibr">135</xref>]. Although perturbation of ROS in preclinical models has so far proved beneficial, to date translation to human disease has been challenging and yielded multiple clinical failures across multiple neurodegenerative diseases [<xref rid="BST-46-829C136" ref-type="bibr">136</xref>]. Interestingly, the antioxidant MitoQ has been assessed in many models of ageing and neurodegenerative disease. MitoQ is a redox active ubiquinone, targeted to mitochondria [<xref rid="BST-46-829C137" ref-type="bibr">137</xref>]. MitoQ has demonstrated positive effects in an SOD1<sup>G93A</sup> ALS mouse model [<xref rid="BST-46-829C138" ref-type="bibr">138</xref>], a triple transgenic AD mouse [<xref rid="BST-46-829C139" ref-type="bibr">139</xref>] and in models of AD in <italic>Caenorhabditis elegans</italic> [<xref rid="BST-46-829C140" ref-type="bibr">140</xref>], together linking mitochondrial ROS and proteinopathy-related neuropathologies. MitoQ is currently in clinical trials testing the efficacy for improving vascular, motor and cognitive function in middle-aged and older adults (NCT02597023).</p></sec></sec><sec id="s4"><title>Conclusion and prospects</title><p>Compelling evidence suggests that mitochondrial dysfunction plays a significant role in neurodegenerative proteinopathies. Neuronal ATP is provided almost exclusively through mitochondrial OXPHOS, and complicated processes controlling mitochondrial dynamics, redox equilibrium, protein import and mitochondrial quality control work in concert to meet spatiotemporal bioenergetic demands. Aberrant misfolded proteins disrupt these processes, triggering mitochondrial dysfunction and having wider effects on cellular homeostasis.</p><p>Numerous disease-modifying strategies targeting mitochondria are currently under investigation. Further development of mPTP inhibitors is warranted due to the emerging evidence of the involvement of Ca<sup>2+</sup> homeostasis, ROS and mPTP opening in multiple neurodegenerative diseases. Accelerating removal of damaged mitochondria has been proposed as a novel disease-modifying strategy not only in PD, but in many proteinopathies. Identification of a mechanism to enhance mitophagy may demand increased understanding of DUB biology and the substrate diversity and selectivity of these enzymes. Clinical trials of mitochondrially targeted antioxidants will provide proof-of-concept concerning ROS manipulation. Taken together, thoroughly understanding the mitochondrial relationship with neurodegenerative proteinopathies is likely to pave the way for the development of targeted therapies, potentially modifying the disease course of these progressive degenerative disorders.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank Jim Staddon for helpful comments and advice in the course of manuscript preparation.</p></ack><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">AD</term><def><p>Alzheimer's disease</p></def></def-item><def-item><term id="uid2">ALS</term><def><p>amyotrophic lateral sclerosis</p></def></def-item><def-item><term id="uid3">ANT</term><def><p>adenine nucleotide translocase</p></def></def-item><def-item><term id="uid4">APP</term><def><p>amyloid precursor protein</p></def></def-item><def-item><term id="uid5">ATP</term><def><p>adenosine triphosphate</p></def></def-item><def-item><term id="uid6">A&#x003b2;</term><def><p>amyloid &#x003b2;</p></def></def-item><def-item><term id="uid7">COX</term><def><p>cytochrome <italic>C</italic> oxidase</p></def></def-item><def-item><term id="uid8">CsA</term><def><p>cyclosporin A</p></def></def-item><def-item><term id="uid9">CypD</term><def><p>cyclophilin D</p></def></def-item><def-item><term id="uid10">DRP-1</term><def><p>dynamin-related protein 1</p></def></def-item><def-item><term id="uid11">DUB</term><def><p>deubiquitinase</p></def></def-item><def-item><term id="uid12">ETC</term><def><p>electron transport chain</p></def></def-item><def-item><term id="uid13">fis1</term><def><p>mitochondrial fission 1</p></def></def-item><def-item><term id="uid14">FTD</term><def><p>frontotemporal dementia</p></def></def-item><def-item><term id="uid15">FUS</term><def><p>fused in sarcoma</p></def></def-item><def-item><term id="uid16">MAM</term><def><p>mitochondrial-associated membrane</p></def></def-item><def-item><term id="uid17">mPTP</term><def><p>mitochondrial permeability transition pore</p></def></def-item><def-item><term id="uid18">OPA-1</term><def><p>optic atrophy 1</p></def></def-item><def-item><term id="uid19">OSCP</term><def><p>oligomycin-sensitivity conferring protein</p></def></def-item><def-item><term id="uid20">OXPHOS</term><def><p>oxidative phosphorylation</p></def></def-item><def-item><term id="uid21">PD</term><def><p>Parkinson's disease</p></def></def-item><def-item><term id="uid22">PINK1</term><def><p>PTEN-induced putative kinase 1</p></def></def-item><def-item><term id="uid23">ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term id="uid24">TDP-43</term><def><p>transactive response DNA-binding protein 43&#x02005;kDa</p></def></def-item><def-item><term id="uid25">TOMM</term><def><p>translocase of the outer mitochondrial membrane</p></def></def-item><def-item><term id="uid26">UPS</term><def><p>ubiquitin&#x02013;proteasome system</p></def></def-item><def-item><term id="uid27">USP</term><def><p>ubiquitin-specific protease</p></def></def-item><def-item><term id="uid28">&#x003b1;-syn</term><def><p>&#x003b1;-synuclein</p></def></def-item></def-list></glossary><sec id="s6"><title>Author Contribution</title><p>T.B. and A.R.H. wrote the manuscript.</p></sec><sec id="s8" sec-type="COI-statement"><title>Competing Interests</title><p>T.B. and A.R.H. are employees of Eisai Ltd.</p></sec><ref-list><title>References</title><ref id="BST-46-829C1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Silver</surname><given-names>I.</given-names></name> and <name name-style="western"><surname>Ereci&#x00144;ska</surname><given-names>M.</given-names></name></person-group> (<year>1998</year>) <chapter-title>Oxygen and ion concentrations in normoxic and hypoxic brain cells</chapter-title> In <source>Oxygen Transport to Tissue XX</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Hudetz</surname><given-names>A.G.</given-names></name>, <name name-style="western"><surname>Bruley</surname><given-names>D.F.</given-names></name></person-group>, eds), pp. <fpage>7</fpage>&#x02013;<lpage>16</lpage>. <publisher-name>Springer</publisher-name>, <publisher-loc>Boston, MA</publisher-loc></mixed-citation></ref><ref id="BST-46-829C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>T.A.</given-names></name></person-group> (<year>2015</year>) <article-title>Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?</article-title>
<source>Eur. Neuropsychopharmacol.</source>
<volume>25</volume>, <fpage>713</fpage>&#x02013;<lpage>724</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2013.03.007</pub-id><pub-id pub-id-type="pmid">23642796</pub-id></mixed-citation></ref><ref id="BST-46-829C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ugalde</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Finkelstein</surname><given-names>D.I.</given-names></name>, <name name-style="western"><surname>Lawson</surname><given-names>V.A.</given-names></name> and <name name-style="western"><surname>Hill</surname><given-names>A.F.</given-names></name></person-group> (<year>2016</year>) <article-title>Pathogenic mechanisms of prion protein, amyloid-&#x003b2; and &#x003b1;-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers</article-title>. <source>J. Neurochem.</source>
<volume>139</volume>, <fpage>162</fpage>&#x02013;<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13772</pub-id><pub-id pub-id-type="pmid">27529376</pub-id></mixed-citation></ref><ref id="BST-46-829C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Swerdlow</surname><given-names>R.H.</given-names></name> and <name name-style="western"><surname>Oliveira</surname><given-names>C.R.</given-names></name></person-group> (<year>2002</year>) <article-title>Induction of cytochrome <italic>c</italic>-mediated apoptosis by amyloid &#x003b2; 25&#x02013;35 requires functional mitochondria</article-title>. <source>Brain Res.</source>
<volume>931</volume>, <fpage>117</fpage>&#x02013;<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(02)02256-4</pub-id><pub-id pub-id-type="pmid">11897097</pub-id></mixed-citation></ref><ref id="BST-46-829C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manczak</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>B.S.</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name></person-group> (<year>2004</year>) <article-title>Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage</article-title>. <source>Neuromolecular Med.</source>
<volume>5</volume>, <fpage>147</fpage>&#x02013;<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1385/NMM:5:2:147</pub-id><pub-id pub-id-type="pmid">15075441</pub-id></mixed-citation></ref><ref id="BST-46-829C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manczak</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name></person-group> (<year>2012</year>) <article-title>Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease</article-title>. <source>Hum. Mol. Genet.</source>
<volume>21</volume>, <fpage>5131</fpage>&#x02013;<lpage>5146</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds360</pub-id><pub-id pub-id-type="pmid">22926141</pub-id></mixed-citation></ref><ref id="BST-46-829C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhein</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Baysang</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Meier</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Bonert</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>M&#x000fc;ller-Spahn</surname><given-names>F.</given-names></name><etal>et al</etal></person-group> (<year>2009</year>) <article-title>Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells</article-title>. <source>Cell. Mol. Neurobiol.</source>
<volume>29</volume>, <fpage>1063</fpage>&#x02013;<lpage>1071</lpage>
<pub-id pub-id-type="doi">10.1007/s10571-009-9398-y</pub-id><pub-id pub-id-type="pmid">19350381</pub-id></mixed-citation></ref><ref id="BST-46-829C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhein</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wiesner</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ittner</surname><given-names>L.M.</given-names></name>, <name name-style="western"><surname>Baysang</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Meier</surname><given-names>F.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Amyloid-&#x003b2; and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>106</volume>, <fpage>20057</fpage>&#x02013;<lpage>20062</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0905529106</pub-id><pub-id pub-id-type="pmid">19897719</pub-id></mixed-citation></ref><ref id="BST-46-829C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>W.D.</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Filley</surname><given-names>C.M.</given-names></name> and <name name-style="western"><surname>Parks</surname><given-names>J.K.</given-names></name></person-group> (<year>1990</year>) <article-title>Cytochrome oxidase deficiency in Alzheimer's disease</article-title>. <source>Neurology</source>
<volume>40</volume>, <fpage>1302</fpage>&#x02013;<lpage>1303</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.40.8.1302</pub-id><pub-id pub-id-type="pmid">2166249</pub-id></mixed-citation></ref><ref id="BST-46-829C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>W.D.</given-names></name>, <name name-style="western"><surname>Ba,</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Filley</surname><given-names>C.M.</given-names></name> and <name name-style="western"><surname>Kleinschmidt-DeMasters</surname><given-names>B.K.</given-names></name></person-group> (<year>1994</year>) <article-title>Electron transport chain defects in Alzheimer's disease brain</article-title>. <source>Neurology</source>
<volume>44</volume>, <fpage>1090</fpage>&#x02013;<lpage>1091</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.44.6.1090</pub-id><pub-id pub-id-type="pmid">8208407</pub-id></mixed-citation></ref><ref id="BST-46-829C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>M.T.</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>D.K.</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>C.H.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>L.M.</given-names></name> and <name name-style="western"><surname>Beal</surname><given-names>M.F.</given-names></name></person-group> (<year>2002</year>) <article-title>High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain</article-title>. <source>Hum. Mol. Genet.</source>
<volume>11</volume>, <fpage>133</fpage>&#x02013;<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.2.133</pub-id><pub-id pub-id-type="pmid">11809722</pub-id></mixed-citation></ref><ref id="BST-46-829C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coskun</surname><given-names>P.E.</given-names></name>, <name name-style="western"><surname>Beal</surname><given-names>M.F.</given-names></name> and <name name-style="western"><surname>Wallace</surname><given-names>D.C.</given-names></name></person-group> (<year>2004</year>) <article-title>Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>101</volume>, <fpage>10726</fpage>&#x02013;<lpage>10731</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0403649101</pub-id><pub-id pub-id-type="pmid">15247418</pub-id></mixed-citation></ref><ref id="BST-46-829C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cenini</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rub</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Bruderek</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Voos</surname><given-names>W.</given-names></name></person-group> (<year>2016</year>) <article-title>Amyloid &#x003b2;-peptides interfere with mitochondrial preprotein import competence by a coaggregation process</article-title>. <source>Mol. Biol. Cell</source>
<volume>27</volume>, <fpage>3257</fpage>&#x02013;<lpage>3272</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e16-05-0313</pub-id><pub-id pub-id-type="pmid">27630262</pub-id></mixed-citation></ref><ref id="BST-46-829C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson Petersen</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Alikhani</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Behbahani</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wiehager</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Pavlov</surname><given-names>P.F.</given-names></name>, <name name-style="western"><surname>Alafuzoff</surname><given-names>I.</given-names></name><etal>et al.</etal></person-group> (<year>2008</year>) <article-title>The amyloid &#x003b2;-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>105</volume>, <fpage>13145</fpage>&#x02013;<lpage>13150</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0806192105</pub-id><pub-id pub-id-type="pmid">18757748</pub-id></mixed-citation></ref><ref id="BST-46-829C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreiner</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Hedskog</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Wiehager</surname><given-names>B.</given-names></name> and <name name-style="western"><surname>Ankarcrona</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>) <article-title>Amyloid-&#x003b2; peptides are generated in mitochondria-associated endoplasmic reticulum membranes</article-title>. <source>J. Alzheimers Dis.</source>
<volume>43</volume>, <fpage>369</fpage>&#x02013;<lpage>374</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-132543</pub-id><pub-id pub-id-type="pmid">25096627</pub-id></mixed-citation></ref><ref id="BST-46-829C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>Jonasson</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Alberico</surname><given-names>E.O.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Scripture</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>R.A.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Interactions between tau and different conformations of tubulin: implications for tau function and mechanism</article-title>. <source>J. Mol. Biol.</source>
<volume>429</volume>, <fpage>1424</fpage>&#x02013;<lpage>1438</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2017.03.018</pub-id><pub-id pub-id-type="pmid">28322917</pub-id></mixed-citation></ref><ref id="BST-46-829C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amadoro</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Corsetti</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Florenzano</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Atlante</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ciotti</surname><given-names>M.T.</given-names></name>, <name name-style="western"><surname>Mongiardi</surname><given-names>M.P.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons</article-title>. <source>Neurobiol. Dis.</source>
<volume>62</volume>, <fpage>489</fpage>&#x02013;<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.10.018</pub-id><pub-id pub-id-type="pmid">24411077</pub-id></mixed-citation></ref><ref id="BST-46-829C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DuBoff</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>G&#x000f6;tz</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Feany</surname><given-names>M.B.</given-names></name></person-group> (<year>2012</year>) <article-title>Tau promotes neurodegeneration via DRP1 mislocalization <italic>in vivo</italic></article-title>. <source>Neuron</source>
<volume>75</volume>, <fpage>618</fpage>&#x02013;<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.06.026</pub-id><pub-id pub-id-type="pmid">22920254</pub-id></mixed-citation></ref><ref id="BST-46-829C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corsetti</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Florenzano</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Atlante</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bobba</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ciotti</surname><given-names>M.T.</given-names></name>, <name name-style="western"><surname>Natale</surname><given-names>F.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease</article-title>. <source>Hum. Mol. Genet.</source>
<volume>24</volume>, <fpage>3058</fpage>&#x02013;<lpage>3081</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv059</pub-id><pub-id pub-id-type="pmid">25687137</pub-id></mixed-citation></ref><ref id="BST-46-829C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.C.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.H.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.P.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin</article-title>. <source>Oncotarget</source>
<volume>7</volume>, <fpage>17356</fpage>&#x02013;<lpage>17368</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.7861</pub-id><pub-id pub-id-type="pmid">26943044</pub-id></mixed-citation></ref><ref id="BST-46-829C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.-C.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.-h.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.-P.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>, <fpage>24756</fpage>
<pub-id pub-id-type="doi">10.1038/srep24756</pub-id><pub-id pub-id-type="pmid">27099072</pub-id></mixed-citation></ref><ref id="BST-46-829C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amadoro</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Corsetti</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Stringaro</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Colone</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>D'Aguanno</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Meli</surname><given-names>G.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration</article-title>. <source>J. Alzheimers Dis.</source>
<volume>21</volume>, <fpage>445</fpage>&#x02013;<lpage>470</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2010-100120</pub-id><pub-id pub-id-type="pmid">20571215</pub-id></mixed-citation></ref><ref id="BST-46-829C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amadoro</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Corsetti</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Atlante</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Florenzano</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Capsoni</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bussani</surname><given-names>R.</given-names></name><etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Interaction between NH-tau fragment and A&#x003b2; in Alzheimer's disease mitochondria contributes to the synaptic deterioration</article-title>. <source>Neurobiol. Aging</source>
<volume>33</volume>, <fpage>833.e1</fpage>&#x02013;<lpage>833.e25</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.08.001</pub-id></mixed-citation></ref><ref id="BST-46-829C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopeikina</surname><given-names>K.J.</given-names></name>, <name name-style="western"><surname>Carlson</surname><given-names>G.A.</given-names></name>, <name name-style="western"><surname>Pitstick</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ludvigson</surname><given-names>A.E.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Luebke</surname><given-names>J.I.</given-names></name><etal>et al.</etal></person-group> (<year>2011</year>) <article-title>Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain</article-title>. <source>Am. J. Pathol.</source>
<volume>179</volume>, <fpage>2071</fpage>&#x02013;<lpage>2082</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2011.07.004</pub-id><pub-id pub-id-type="pmid">21854751</pub-id></mixed-citation></ref><ref id="BST-46-829C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoothoff</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>P.B.</given-names></name>, <name name-style="western"><surname>Spires-Jones</surname><given-names>T.L.</given-names></name>, <name name-style="western"><surname>Joyner</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Chhabra</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Bercury</surname><given-names>K.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport</article-title>. <source>J. Neurochem.</source>
<volume>111</volume>, <fpage>417</fpage>&#x02013;<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06316.x</pub-id><pub-id pub-id-type="pmid">19686388</pub-id></mixed-citation></ref><ref id="BST-46-829C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melov</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Adlard</surname><given-names>P.A.</given-names></name>, <name name-style="western"><surname>Morten</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Golden</surname><given-names>T.R.</given-names></name>, <name name-style="western"><surname>Hinerfeld</surname><given-names>D.</given-names></name><etal>et al.</etal></person-group> (<year>2007</year>) <article-title>Mitochondrial oxidative stress causes hyperphosphorylation of tau</article-title>. <source>PLoS ONE</source>
<volume>2</volume>, <fpage>e536</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0000536</pub-id><pub-id pub-id-type="pmid">17579710</pub-id></mixed-citation></ref><ref id="BST-46-829C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merkwirth</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Martinelli</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Korwitz</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Morbin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bronneke</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>S.D.</given-names></name><etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Loss of prohibitin membrane scaffolds impairs mitochondrial architecture and leads to tau hyperphosphorylation and neurodegeneration</article-title>. <source>PLoS Genet.</source>
<volume>8</volume>, <fpage>e1003021</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003021</pub-id><pub-id pub-id-type="pmid">23144624</pub-id></mixed-citation></ref><ref id="BST-46-829C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>D.F.</given-names></name>, <name name-style="western"><surname>Esteves</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>C.R.</given-names></name> and <name name-style="western"><surname>Cardoso</surname><given-names>S.M.</given-names></name></person-group> (<year>2011</year>) <article-title>Mitochondria: the common upstream driver of amyloid-&#x003b2; and tau pathology in Alzheimer's disease</article-title>. <source>Curr. Alzheimer Res.</source>
<volume>8</volume>, <fpage>563</fpage>&#x02013;<lpage>572</lpage>
<pub-id pub-id-type="doi">10.2174/156720511796391872</pub-id><pub-id pub-id-type="pmid">21244356</pub-id></mixed-citation></ref><ref id="BST-46-829C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iijima-Ando</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Sekiya</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Maruko-Otake</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ohtake</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1</article-title>. <source>PLoS Genet.</source>
<volume>8</volume>, <fpage>e1002918</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002918</pub-id><pub-id pub-id-type="pmid">22952452</pub-id></mixed-citation></ref><ref id="BST-46-829C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joh</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Choi</surname><given-names>W.-S.</given-names></name></person-group> (<year>2017</year>) <article-title>Mitochondrial complex I inhibition accelerates amyloid toxicity</article-title>. <source>Dev. Reprod.</source>
<volume>21</volume>, <fpage>417</fpage>&#x02013;<lpage>424</lpage>
<pub-id pub-id-type="doi">10.12717/DR.2017.21.4.417</pub-id><pub-id pub-id-type="pmid">29354787</pub-id></mixed-citation></ref><ref id="BST-46-829C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunetti</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Torsvik</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Dallabona</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Teixeira</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Sztromwasser</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Fernandez-Vizarra</surname><given-names>E.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Defective PITRM1 mitochondrial peptidase is associated with A&#x003b2; amyloidotic neurodegeneration</article-title>. <source>EMBO Mol. Med.</source>
<volume>8</volume>, <fpage>176</fpage>&#x02013;<lpage>190</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201505894</pub-id><pub-id pub-id-type="pmid">26697887</pub-id></mixed-citation></ref><ref id="BST-46-829C32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alikhani</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Pinho</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.X.</given-names></name><etal>et al.</etal></person-group> (<year>2011</year>) <article-title>Decreased proteolytic activity of the mitochondrial amyloid-&#x003b2; degrading enzyme, PreP peptidasome, in Alzheimer's disease brain mitochondria</article-title>. <source>J. Alzheimers Dis.</source>
<volume>27</volume>, <fpage>75</fpage>&#x02013;<lpage>87</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2011-101716</pub-id><pub-id pub-id-type="pmid">21750375</pub-id></mixed-citation></ref><ref id="BST-46-829C33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falkevall</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Alikhani</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bhushan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Pavlov</surname><given-names>P.F.</given-names></name>, <name name-style="western"><surname>Busch</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>K.A.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Degradation of the amyloid &#x003b2;-protein by the novel mitochondrial peptidasome, PreP</article-title>. <source>J. Biol. Chem.</source>
<volume>281</volume>, <fpage>29096</fpage>&#x02013;<lpage>29104</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M602532200</pub-id><pub-id pub-id-type="pmid">16849325</pub-id></mixed-citation></ref><ref id="BST-46-829C34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.J.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>J.I.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Jo</surname><given-names>Y.K.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>E.S.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Down-regulation of Mortalin exacerbates A&#x003b2;-mediated mitochondrial fragmentation and dysfunction</article-title>. <source>J. Biol. Chem.</source>
<volume>289</volume>, <fpage>2195</fpage>&#x02013;<lpage>2204</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.492587</pub-id><pub-id pub-id-type="pmid">24324263</pub-id></mixed-citation></ref><ref id="BST-46-829C35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name> and <name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>) <article-title>Mortalin overexpression attenuates beta-amyloid-induced neurotoxicity in SH-SY5Y cells</article-title>. <source>Brain Res.</source>
<volume>1368</volume>, <fpage>336</fpage>&#x02013;<lpage>345</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.10.068</pub-id><pub-id pub-id-type="pmid">20974113</pub-id></mixed-citation></ref><ref id="BST-46-829C36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondadi</surname><given-names>A.K.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Montagner</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kladt</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Korwitz</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Martinelli</surname><given-names>P.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Loss of the m-AAA protease subunit AFG3L2 causes mitochondrial transport defects and tau hyperphosphorylation</article-title>. <source>EMBO J.</source>
<volume>33</volume>, <fpage>1011</fpage>&#x02013;<lpage>1026</lpage>
<pub-id pub-id-type="doi">10.1002/embj.201387009</pub-id><pub-id pub-id-type="pmid">24681487</pub-id></mixed-citation></ref><ref id="BST-46-829C37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>S.J.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Phensy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Tandon</surname><given-names>N.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease</article-title>. <source>Nat. Commun.</source>
<volume>7</volume>, <fpage>11483</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms11483</pub-id><pub-id pub-id-type="pmid">27151236</pub-id></mixed-citation></ref><ref id="BST-46-829C38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Rydzewska</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>) <article-title>Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model</article-title>. <source>Neurobiol. Aging</source>
<volume>32</volume>, <fpage>398</fpage>&#x02013;<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.03.003</pub-id><pub-id pub-id-type="pmid">19362755</pub-id></mixed-citation></ref><ref id="BST-46-829C39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bose</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Beal</surname><given-names>M.F.</given-names></name></person-group> (<year>2016</year>) <article-title>Mitochondrial dysfunction in Parkinson's disease</article-title>. <source>J. Neurochem.</source>
<volume>139</volume>(<issue>Suppl 1</issue>), <fpage>216</fpage>&#x02013;<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13731</pub-id><pub-id pub-id-type="pmid">27546335</pub-id></mixed-citation></ref><ref id="BST-46-829C40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hoffer</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hoffer</surname><given-names>B.</given-names></name> and <name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name></person-group> (<year>2015</year>) <article-title>Mitochondria: a therapeutic target for Parkinson's disease?</article-title>
<source>Int. J. Mol. Sci.</source>
<volume>16</volume>, <fpage>20704</fpage>&#x02013;<lpage>20730</lpage>
<pub-id pub-id-type="doi">10.3390/ijms160920704</pub-id><pub-id pub-id-type="pmid">26340618</pub-id></mixed-citation></ref><ref id="BST-46-829C41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osellame</surname><given-names>L.D.</given-names></name>, <name name-style="western"><surname>Rahim</surname><given-names>A.A.</given-names></name>, <name name-style="western"><surname>Hargreaves</surname><given-names>I.P.</given-names></name>, <name name-style="western"><surname>Gegg</surname><given-names>M.E.</given-names></name>, <name name-style="western"><surname>Richard-Londt</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Brandner</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Mitochondria and quality control defects in a mouse model of Gaucher disease&#x02014;links to Parkinson's disease</article-title>. <source>Cell Metab.</source>
<volume>17</volume>, <fpage>941</fpage>&#x02013;<lpage>953</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.014</pub-id><pub-id pub-id-type="pmid">23707074</pub-id></mixed-citation></ref><ref id="BST-46-829C42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickrell</surname><given-names>A.M.</given-names></name> and <name name-style="western"><surname>Youle</surname><given-names>R.J.</given-names></name></person-group> (<year>2015</year>) <article-title>The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease</article-title>. <source>Neuron</source>
<volume>85</volume>, <fpage>257</fpage>&#x02013;<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.007</pub-id><pub-id pub-id-type="pmid">25611507</pub-id></mixed-citation></ref><ref id="BST-46-829C43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valente</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Abou-Sleiman</surname><given-names>P.M.</given-names></name>, <name name-style="western"><surname>Caputo</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Muqit</surname><given-names>M.M.K.</given-names></name>, <name name-style="western"><surname>Harvey</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Gispert</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2004</year>) <article-title>Hereditary early-onset Parkinson's disease caused by mutations in PINK1</article-title>. <source>Science</source>
<volume>304</volume>, <fpage>1158</fpage>&#x02013;<lpage>1160</lpage>
<pub-id pub-id-type="doi">10.1126/science.1096284</pub-id><pub-id pub-id-type="pmid">15087508</pub-id></mixed-citation></ref><ref id="BST-46-829C44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>M.W.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Huh</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Seol</surname><given-names>J.H.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin</article-title>. <source>Nature</source>
<volume>441</volume>, <fpage>1162</fpage>&#x02013;<lpage>1166</lpage>
<pub-id pub-id-type="doi">10.1038/nature04779</pub-id><pub-id pub-id-type="pmid">16672981</pub-id></mixed-citation></ref><ref id="BST-46-829C45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S.B.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Mitochondrial dysfunction in <italic>Drosophila</italic> PINK1 mutants is complemented by parkin</article-title>. <source>Nature</source>
<volume>441</volume>, <fpage>1157</fpage>&#x02013;<lpage>1161</lpage>
<pub-id pub-id-type="doi">10.1038/nature04788</pub-id><pub-id pub-id-type="pmid">16672980</pub-id></mixed-citation></ref><ref id="BST-46-829C46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinta</surname><given-names>S.J.</given-names></name>, <name name-style="western"><surname>Mallajosyula</surname><given-names>J.K.</given-names></name>, <name name-style="western"><surname>Rane</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Andersen</surname><given-names>J.K.</given-names></name></person-group> (<year>2010</year>) <article-title>Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy <italic>in vivo</italic></article-title>. <source>Neurosci. Lett.</source>
<volume>486</volume>, <fpage>235</fpage>&#x02013;<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.09.061</pub-id><pub-id pub-id-type="pmid">20887775</pub-id></mixed-citation></ref><ref id="BST-46-829C47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindstr&#x000f6;m</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Gustafsson</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>L.H.</given-names></name>, <name name-style="western"><surname>Howlett</surname><given-names>E.H.</given-names></name>, <name name-style="western"><surname>Sigvardson</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Kasrayan</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Extensive uptake of &#x003b1;-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage</article-title>. <source>Mol. Cell Neurosci.</source>
<volume>82</volume>, <fpage>143</fpage>&#x02013;<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2017.04.009</pub-id><pub-id pub-id-type="pmid">28450268</pub-id></mixed-citation></ref><ref id="BST-46-829C48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puka&#x000df;</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Goldbaum</surname><given-names>O.</given-names></name> and <name name-style="western"><surname>Richter-Landsberg</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>) <article-title>Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of &#x003b1;-synuclein in oligodendroglial cells</article-title>. <source>J. Neurochem.</source>
<volume>135</volume>, <fpage>194</fpage>&#x02013;<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13256</pub-id><pub-id pub-id-type="pmid">26212128</pub-id></mixed-citation></ref><ref id="BST-46-829C49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherer</surname><given-names>T.B.</given-names></name>, <name name-style="western"><surname>Betarbet</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Stout</surname><given-names>A.K.</given-names></name>, <name name-style="western"><surname>Lund</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Baptista</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Panov</surname><given-names>A.V.</given-names></name><etal>et al.</etal></person-group> (<year>2002</year>) <article-title>An <italic>in vitro</italic> model of Parkinson's disease: linking mitochondrial impairment to altered &#x003b1;-synuclein metabolism and oxidative damage</article-title>. <source>J. Neurosci.</source>
<volume>22</volume>, <fpage>7006</fpage>&#x02013;<lpage>7015</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-16-07006.2002</pub-id><pub-id pub-id-type="pmid">12177198</pub-id></mixed-citation></ref><ref id="BST-46-829C50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>S.Y.</given-names></name>, <name name-style="western"><surname>Kishinevsky</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mazzulli</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Graziotto</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Mrejeru</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mosharov</surname><given-names>E.V.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and &#x003b1;-synuclein accumulation</article-title>. <source>Stem Cell Rep.</source>
<volume>7</volume>, <fpage>664</fpage>&#x02013;<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2016.08.012</pub-id></mixed-citation></ref><ref id="BST-46-829C51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>C.-H.</given-names></name>, <name name-style="western"><surname>Shaltouki</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>A.E.</given-names></name>, <name name-style="western"><surname>Bettencourt da Cruz</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Burbulla</surname><given-names>L.F.</given-names></name>, <name name-style="western"><surname>St Lawrence</surname><given-names>E.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease</article-title>. <source>Cell Stem Cell</source>
<volume>19</volume>, <fpage>709</fpage>&#x02013;<lpage>724</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2016.08.002</pub-id><pub-id pub-id-type="pmid">27618216</pub-id></mixed-citation></ref><ref id="BST-46-829C52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burchell</surname><given-names>V.S.</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>D.E.</given-names></name>, <name name-style="western"><surname>Sanchez-Martinez</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Delgado-Camprubi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ivatt</surname><given-names>R.M.</given-names></name>, <name name-style="western"><surname>Pogson</surname><given-names>J.H.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy</article-title>. <source>Nat. Neurosci.</source>
<volume>16</volume>, <fpage>1257</fpage>&#x02013;<lpage>1265</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3489</pub-id><pub-id pub-id-type="pmid">23933751</pub-id></mixed-citation></ref><ref id="BST-46-829C53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.D.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>S.P.</given-names></name>, <name name-style="western"><surname>Sathiyamoorthy</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Saw</surname><given-names>W.T.</given-names></name>, <name name-style="western"><surname>Sing</surname><given-names>T.Y.</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>S.H.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy</article-title>. <source>Hum. Mol. Genet.</source>
<volume>24</volume>, <fpage>6314</fpage>&#x02013;<lpage>6330</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv340</pub-id><pub-id pub-id-type="pmid">26310625</pub-id></mixed-citation></ref><ref id="BST-46-829C54"><label>54</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>K.A.</given-names></name></person-group> (<year>2010</year>) <source>Synucleinopathies. Encyclopedia of Movement Disorders</source>, pp. <fpage>203</fpage>&#x02013;<lpage>207</lpage>. <publisher-name>Academic Press</publisher-name>, <publisher-loc>Oxford</publisher-loc></mixed-citation></ref><ref id="BST-46-829C55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Sagara</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Arroyo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Rockenstein</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sisk</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mallory</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2000</year>) <article-title>&#x003b1;-synuclein promotes mitochondrial deficit and oxidative stress</article-title>. <source>Am. J. Pathol.</source>
<volume>157</volume>, <fpage>401</fpage>&#x02013;<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)64553-1</pub-id><pub-id pub-id-type="pmid">10934145</pub-id></mixed-citation></ref><ref id="BST-46-829C56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Sterling</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Copeland</surname><given-names>N.G.</given-names></name>, <name name-style="western"><surname>Jenkins</surname><given-names>N.A.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Parkinson's disease &#x003b1;-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death</article-title>. <source>J. Neurosci.</source>
<volume>26</volume>, <fpage>41</fpage>&#x02013;<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4308-05.2006</pub-id><pub-id pub-id-type="pmid">16399671</pub-id></mixed-citation></ref><ref id="BST-46-829C57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Raghavendran</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Prabhu</surname><given-names>B.M.</given-names></name>, <name name-style="western"><surname>Avadhani</surname><given-names>N.G.</given-names></name> and <name name-style="western"><surname>Anandatheerthavarada</surname><given-names>H.K.</given-names></name></person-group> (<year>2008</year>) <article-title>Mitochondrial import and accumulation of &#x003b1;-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain</article-title>. <source>J. Biol. Chem.</source>
<volume>283</volume>, <fpage>9089</fpage>&#x02013;<lpage>9100</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M710012200</pub-id><pub-id pub-id-type="pmid">18245082</pub-id></mixed-citation></ref><ref id="BST-46-829C58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guardia-Laguarta</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Area-Gomez</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Rub</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Magrane</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>D.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>&#x003b1;-synuclein is localized to mitochondria-associated ER membranes</article-title>. <source>J. Neurosci.</source>
<volume>34</volume>, <fpage>249</fpage>&#x02013;<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2507-13.2014</pub-id><pub-id pub-id-type="pmid">24381286</pub-id></mixed-citation></ref><ref id="BST-46-829C59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozo Devoto</surname><given-names>V.M.</given-names></name>, <name name-style="western"><surname>Dimopoulos</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Alloatti</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pardi</surname><given-names>M.B.</given-names></name>, <name name-style="western"><surname>Saez</surname><given-names>T.M.</given-names></name>, <name name-style="western"><surname>Otero</surname><given-names>M.G.</given-names></name><etal>et al</etal></person-group> (<year>2017</year>) <article-title>&#x003b1;synuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <year>5042</year>
<pub-id pub-id-type="doi">10.1038/s41598-017-05334-9</pub-id></mixed-citation></ref><ref id="BST-46-829C60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Nemani</surname><given-names>V.M.</given-names></name>, <name name-style="western"><surname>Azarbal</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Skibinski</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Egami</surname><given-names>K.</given-names></name><etal>et al.</etal></person-group> (<year>2011</year>) <article-title>Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein &#x003b1;-synuclein</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume>, <fpage>20710</fpage>&#x02013;<lpage>20726</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.213538</pub-id><pub-id pub-id-type="pmid">21489994</pub-id></mixed-citation></ref><ref id="BST-46-829C61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Maio</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Hoffman</surname><given-names>E.K.</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>C.W.</given-names></name>, <name name-style="western"><surname>Zharikov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Borah</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>&#x003b1;-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease</article-title>. <source>Sci. Transl. Med.</source>
<volume>8</volume>, <fpage>342ra78</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaf3634</pub-id></mixed-citation></ref><ref id="BST-46-829C62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Turkson</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Zhuang</surname><given-names>X.</given-names></name></person-group> (<year>2015</year>) <article-title>A53T human &#x003b1;-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration</article-title>. <source>J. Neurosci.</source>
<volume>35</volume>, <fpage>890</fpage>&#x02013;<lpage>905</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0089-14.2015</pub-id><pub-id pub-id-type="pmid">25609609</pub-id></mixed-citation></ref><ref id="BST-46-829C63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gispert</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Brehm</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Weil</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Seidel</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>R&#x000fc;b</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Kern</surname><given-names>B.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression</article-title>. <source>Hum. Mol. Genet.</source>
<volume>24</volume>, <fpage>1061</fpage>&#x02013;<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu520</pub-id><pub-id pub-id-type="pmid">25296918</pub-id></mixed-citation></ref><ref id="BST-46-829C64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Bamm</surname><given-names>V.V.</given-names></name>, <name name-style="western"><surname>Stykel</surname><given-names>M.G.</given-names></name>, <name name-style="western"><surname>Coackley</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Humphries</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Jamieson-Williams</surname><given-names>R.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Cardiolipin exposure on the outer mitochondrial membrane modulates &#x003b1;-synuclein</article-title>. <source>Nat. Commun.</source>
<volume>9</volume>, <fpage>817</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-03241-9</pub-id><pub-id pub-id-type="pmid">29483518</pub-id></mixed-citation></ref><ref id="BST-46-829C65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ordonez</surname><given-names>D.G.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>M.K.</given-names></name> and <name name-style="western"><surname>Feany</surname><given-names>M.B.</given-names></name></person-group> (<year>2018</year>) <article-title>&#x003b1;-synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton</article-title>. <source>Neuron</source>
<volume>97</volume>, <fpage>108</fpage>&#x02013;<lpage>24.e6</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.11.036</pub-id><pub-id pub-id-type="pmid">29249285</pub-id></mixed-citation></ref><ref id="BST-46-829C66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keeney</surname><given-names>P.M.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Capaldi</surname><given-names>R.A.</given-names></name> and <name name-style="western"><surname>Bennett</surname><given-names>J.P.</given-names></name></person-group> (<year>2006</year>) <article-title>Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled</article-title>. <source>J. Neurosci.</source>
<volume>26</volume>, <fpage>5256</fpage>&#x02013;<lpage>5264</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0984-06.2006</pub-id><pub-id pub-id-type="pmid">16687518</pub-id></mixed-citation></ref><ref id="BST-46-829C67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year><article-title>) &#x003b1;-Synuclein amino terminus regulates mitochondrial membrane permeability</article-title>. <source>Brain Res.</source>
<year>1591</year>, <fpage>14</fpage>&#x02013;<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.09.046</pub-id></mixed-citation></ref><ref id="BST-46-829C68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrari</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kapogiannis</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Huey</surname><given-names>E.D.</given-names></name> and <name name-style="western"><surname>Momeni</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>) <article-title>FTD and ALS: a tale of two diseases</article-title>. <source>Curr. Alzheimer Res.</source>
<volume>8</volume>, <fpage>273</fpage>&#x02013;<lpage>294</lpage>
<pub-id pub-id-type="doi">10.2174/156720511795563700</pub-id><pub-id pub-id-type="pmid">21222600</pub-id></mixed-citation></ref><ref id="BST-46-829C69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muyderman</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>) <article-title>Mitochondrial dysfunction in amyotrophic lateral sclerosis &#x02014; a valid pharmacological target?</article-title>
<source>Br. J. Pharmacol.</source>
<volume>171</volume>, <fpage>2191</fpage>&#x02013;<lpage>2205</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12476</pub-id><pub-id pub-id-type="pmid">24148000</pub-id></mixed-citation></ref><ref id="BST-46-829C70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.-J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><etal>et al.</etal></person-group> (<year>2011</year>) <article-title>FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration</article-title>. <source>PLoS Genet.</source>
<volume>7</volume>, <fpage>e1002011</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1002011</pub-id><pub-id pub-id-type="pmid">21408206</pub-id></mixed-citation></ref><ref id="BST-46-829C71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Geser</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name>, <name name-style="western"><surname>Strober</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions</article-title>. <source>Brain Pathol.</source>
<volume>20</volume>, <fpage>1069</fpage>&#x02013;<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1111/j.1750-3639.2010.00413.x</pub-id><pub-id pub-id-type="pmid">20579074</pub-id></mixed-citation></ref><ref id="BST-46-829C72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chiang</surname><given-names>P.-M.</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>D.L.</given-names></name> and <name name-style="western"><surname>Wong</surname><given-names>P.C.</given-names></name></person-group> (<year>2010</year>) <article-title>Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>107</volume>, <fpage>16325</fpage>&#x02013;<lpage>16330</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1003459107</pub-id><pub-id pub-id-type="pmid">20736350</pub-id></mixed-citation></ref><ref id="BST-46-829C73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.-F.</given-names></name>, <name name-style="western"><surname>Gendron</surname><given-names>T.F.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.-J.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>W.-L.</given-names></name>, <name name-style="western"><surname>D'Alton</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sheng</surname><given-names>H.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice</article-title>. <source>J. Neurosci.</source>
<volume>30</volume>, <fpage>10851</fpage>&#x02013;<lpage>10859</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1630-10.2010</pub-id><pub-id pub-id-type="pmid">20702714</pub-id></mixed-citation></ref><ref id="BST-46-829C74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Itaman</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Khalid-Janney</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Sherard</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Dowell</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Cairns</surname><given-names>N.J.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics</article-title>. <source>Neurosci. Lett.</source>
<volume>678</volume>, <fpage>8</fpage>&#x02013;<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2018.04.053</pub-id><pub-id pub-id-type="pmid">29715546</pub-id></mixed-citation></ref><ref id="BST-46-829C75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>W.-L.</given-names></name>, <name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name>, <name name-style="western"><surname>Petrucelli</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons</article-title>. <source>Hum. Mol. Genet.</source>
<volume>22</volume>, <fpage>4706</fpage>&#x02013;<lpage>4719</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt319</pub-id><pub-id pub-id-type="pmid">23827948</pub-id></mixed-citation></ref><ref id="BST-46-829C76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supnet</surname><given-names>C.</given-names></name> and <name name-style="western"><surname>Bezprozvanny</surname><given-names>I.</given-names></name></person-group> (<year>2010</year>) <article-title>Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease</article-title>. <source>J. Alzheimers Dis.</source>
<volume>20</volume>(<issue>Suppl 2</issue>), <fpage>S487</fpage>&#x02013;<lpage>S498</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2010-100306</pub-id><pub-id pub-id-type="pmid">20413848</pub-id></mixed-citation></ref><ref id="BST-46-829C77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supnet</surname><given-names>C.</given-names></name> and <name name-style="western"><surname>Bezprozvanny</surname><given-names>I.</given-names></name></person-group> (<year>2010</year>) <article-title>The dysregulation of intracellular calcium in Alzheimer disease</article-title>. <source>Cell Calcium</source>
<volume>47</volume>, <fpage>183</fpage>&#x02013;<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceca.2009.12.014</pub-id><pub-id pub-id-type="pmid">20080301</pub-id></mixed-citation></ref><ref id="BST-46-829C78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pivovarova</surname><given-names>N.B.</given-names></name> and <name name-style="western"><surname>Andrews</surname><given-names>S.B.</given-names></name></person-group> (<year>2010</year>) <article-title>Calcium-dependent mitochondrial function and dysfunction in neurons</article-title>. <source>FEBS J.</source>
<volume>277</volume>, <fpage>3622</fpage>&#x02013;<lpage>3636</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07754.x</pub-id><pub-id pub-id-type="pmid">20659161</pub-id></mixed-citation></ref><ref id="BST-46-829C79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haworth</surname><given-names>R.A.</given-names></name> and <name name-style="western"><surname>Hunter</surname><given-names>D.R.</given-names></name></person-group> (<year>1979</year>) <article-title>The Ca<sup>2+</sup>-induced membrane transition in mitochondria. II. Nature of the Ca<sup>2+</sup> trigger site</article-title>. <source>Arch. Biochem. Biophys.</source>
<volume>195</volume>, <fpage>460</fpage>&#x02013;<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1016/0003-9861(79)90372-2</pub-id><pub-id pub-id-type="pmid">38751</pub-id></mixed-citation></ref><ref id="BST-46-829C80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szab&#x000f3;</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Zoratti</surname><given-names>M.</given-names></name></person-group> (<year>1992</year>) <article-title>Modulation of the mitochondrial megachannel by divalent cations and protons</article-title>. <source>J. Biol. Chem.</source>
<volume>267</volume>, <fpage>2940</fpage>&#x02013;<lpage>2946</lpage> PMID:<pub-id pub-id-type="pmid">1371109</pub-id></mixed-citation></ref><ref id="BST-46-829C81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardi</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Vassanelli</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Veronese</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Colonna</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Szab&#x000f3;</surname><given-names>I.</given-names></name> and <name name-style="western"><surname>Zoratti</surname><given-names>M.</given-names></name></person-group> (<year>1992</year>) <article-title>Modulation of the mitochondrial permeability transition pore. Effect of protons and divalent cations</article-title>. <source>J. Biol. Chem.</source>
<volume>267</volume>, <fpage>2934</fpage>&#x02013;<lpage>2939</lpage> PMID:<pub-id pub-id-type="pmid">1737749</pub-id></mixed-citation></ref><ref id="BST-46-829C82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scorrano</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Petronilli</surname><given-names>V.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>P.</given-names></name></person-group> (<year>1997</year>) <article-title>On the voltage dependence of the mitochondrial permeability transition pore. A critical appraisal</article-title>. <source>J. Biol. Chem.</source>
<volume>272</volume>, <fpage>12295</fpage>&#x02013;<lpage>12299</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.272.19.12295</pub-id><pub-id pub-id-type="pmid">9139672</pub-id></mixed-citation></ref><ref id="BST-46-829C83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crompton</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>) <article-title>The mitochondrial permeability transition pore and its role in cell death</article-title>. <source>Biochem. J.</source>
<volume>341</volume>, <fpage>233</fpage>&#x02013;<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1042/bj3410233</pub-id><pub-id pub-id-type="pmid">10393078</pub-id></mixed-citation></ref><ref id="BST-46-829C84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briston</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Powney</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Staddon</surname><given-names>J.M</given-names></name>, <name name-style="western"><surname>Szabadkai</surname><given-names>G.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Mitochondrial permeability transition pore: sensitivity to opening and mechanistic dependence on substrate availability</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>10492</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-10673-8</pub-id><pub-id pub-id-type="pmid">28874733</pub-id></mixed-citation></ref><ref id="BST-46-829C85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crompton</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ellinger</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Costi</surname><given-names>A.</given-names></name></person-group> (<year>1988</year>) <article-title>Inhibition by cyclosporin A of a Ca<sup>2+</sup>-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress</article-title>. <source>Biochem. J.</source>
<volume>255</volume>, <fpage>357</fpage>&#x02013;<lpage>360</lpage> PMID:<pub-id pub-id-type="pmid">3196322</pub-id></mixed-citation></ref><ref id="BST-46-829C86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baines</surname><given-names>C.P.</given-names></name>, <name name-style="western"><surname>Kaiser</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Purcell</surname><given-names>N.H.</given-names></name>, <name name-style="western"><surname>Blair</surname><given-names>N.S.</given-names></name>, <name name-style="western"><surname>Osinska</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hambleton</surname><given-names>M.A.</given-names></name><etal>et al.</etal></person-group> (<year>2005</year>) <article-title>Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death</article-title>. <source>Nature</source>
<volume>434</volume>, <fpage>658</fpage>&#x02013;<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1038/nature03434</pub-id><pub-id pub-id-type="pmid">15800627</pub-id></mixed-citation></ref><ref id="BST-46-829C87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Sosunov</surname><given-names>A.A.</given-names></name>, <name name-style="western"><surname>McKhann</surname><given-names>G.M.</given-names></name><etal>et al.</etal></person-group> (<year>2008</year>) <article-title>Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease</article-title>. <source>Nat. Med.</source>
<volume>14</volume>, <fpage>1097</fpage>&#x02013;<lpage>1105</lpage>
<pub-id pub-id-type="doi">10.1038/nm.1868</pub-id><pub-id pub-id-type="pmid">18806802</pub-id></mixed-citation></ref><ref id="BST-46-829C88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>McKhann</surname><given-names>G.M.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.X.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer's neurons</article-title>. <source>PLoS ONE</source>
<volume>8</volume>, <fpage>e54914</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0054914</pub-id><pub-id pub-id-type="pmid">23382999</pub-id></mixed-citation></ref><ref id="BST-46-829C89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giorgio</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Bisetto</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Soriano</surname><given-names>M.E.</given-names></name>, <name name-style="western"><surname>Dabbeni-Sala</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Basso</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Petronilli</surname><given-names>V.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Cyclophilin D modulates mitochondrial F<sub>0</sub>F<sub>1</sub>-ATP synthase by interacting with the lateral stalk of the complex</article-title>. <source>J. Biol. Chem.</source>
<volume>284</volume>, <fpage>33982</fpage>&#x02013;<lpage>33988</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.020115</pub-id><pub-id pub-id-type="pmid">19801635</pub-id></mixed-citation></ref><ref id="BST-46-829C90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giorgio</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>von Stockum</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Antoniel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fabbro</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Fogolari</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Forte</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Dimers of mitochondrial ATP synthase form the permeability transition pore</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>110</volume>, <fpage>5887</fpage>&#x02013;<lpage>5892</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1217823110</pub-id><pub-id pub-id-type="pmid">23530243</pub-id></mixed-citation></ref><ref id="BST-46-829C91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elkamhawy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J.-e.</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>A.H.E.</given-names></name>, <name name-style="western"><surname>Pae</surname><given-names>A.N.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>B.-G.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of A&#x003b2;-induced mitochondrial dysfunction in Alzheimer's disease</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>144</volume>, <fpage>529</fpage>&#x02013;<lpage>543</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmech.2017.12.045</pub-id><pub-id pub-id-type="pmid">29288949</pub-id></mixed-citation></ref><ref id="BST-46-829C92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.-e.</given-names></name>, <name name-style="western"><surname>Elkamhawy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>A.H.E.</given-names></name>, <name name-style="western"><surname>Pae</surname><given-names>A.N.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Paik</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: neuroprotection against amyloid-&#x003b2;-induced toxicity</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>141</volume>, <fpage>322</fpage>&#x02013;<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmech.2017.09.043</pub-id><pub-id pub-id-type="pmid">29031076</pub-id></mixed-citation></ref><ref id="BST-46-829C93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valasani</surname><given-names>K.R.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Identification of a small molecule cyclophilin D inhibitor for rescuing A&#x003b2;-mediated mitochondrial dysfunction</article-title>. <source>ACS Med. Chem. Lett.</source>
<volume>7</volume>, <fpage>294</fpage>&#x02013;<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00451</pub-id><pub-id pub-id-type="pmid">26985318</pub-id></mixed-citation></ref><ref id="BST-46-829C94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>S.h.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>B.-G.</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>M.K.</given-names></name>, <name name-style="western"><surname>Jang</surname><given-names>H.-S.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>62</volume>, <fpage>71</fpage>&#x02013;<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmech.2012.12.033</pub-id><pub-id pub-id-type="pmid">23353734</pub-id></mixed-citation></ref><ref id="BST-46-829C95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodfield</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>R&#x000fc;ck</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Brdiczka</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Halestrap</surname><given-names>A.P.</given-names></name></person-group> (<year>1998</year>) <article-title>Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition</article-title>. <source>Biochem. J.</source>
<volume>336</volume>(<issue>Pt 2</issue>), <fpage>287</fpage>&#x02013;<lpage>290</lpage>
<pub-id pub-id-type="doi">10.1042/bj3360287</pub-id><pub-id pub-id-type="pmid">9820802</pub-id></mixed-citation></ref><ref id="BST-46-829C96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>A.P.</given-names></name> and <name name-style="western"><surname>Halestrap</surname><given-names>A.P.</given-names></name></person-group> (<year>2016</year>) <article-title>Quantification of active mitochondrial permeability transition pores using GNX-4975 inhibitor titrations provides insights into molecular identity</article-title>. <source>Biochem. J.</source>
<volume>473</volume>, <fpage>1129</fpage>&#x02013;<lpage>1140</lpage>
<pub-id pub-id-type="doi">10.1042/BCJ20160070</pub-id><pub-id pub-id-type="pmid">26920024</pub-id></mixed-citation></ref><ref id="BST-46-829C97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>L&#x000fc;</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2011</year>) <article-title>&#x003b1;-Synuclein overexpression impairs mitochondrial function by associating with adenylate translocator</article-title>. <source>Int. J. Biochem. Cell Biol.</source>
<volume>43</volume>, <fpage>732</fpage>&#x02013;<lpage>741</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2011.01.014</pub-id><pub-id pub-id-type="pmid">21310263</pub-id></mixed-citation></ref><ref id="BST-46-829C98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Heitman</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>) <article-title>The cyclophilins</article-title>. <source>Genome Biol.</source>
<volume>6</volume>, <fpage>226</fpage>
<pub-id pub-id-type="doi">10.1186/gb-2005-6-7-226</pub-id><pub-id pub-id-type="pmid">15998457</pub-id></mixed-citation></ref><ref id="BST-46-829C99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basso</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Fante</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fowlkes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Petronilli</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Forte</surname><given-names>M.A.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>P.</given-names></name></person-group> (<year>2005</year>) <article-title>Properties of the permeability transition pore in mitochondria devoid of cyclophilin D</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>18558</fpage>&#x02013;<lpage>18561</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.C500089200</pub-id><pub-id pub-id-type="pmid">15792954</pub-id></mixed-citation></ref><ref id="BST-46-829C100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halestrap</surname><given-names>A.P.</given-names></name> and <name name-style="western"><surname>Davidson</surname><given-names>A.M.</given-names></name></person-group> (<year>1990</year>) <article-title>Inhibition of Ca<sup>2+</sup>-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl <italic>cis-trans</italic> isomerase and preventing it interacting with the adenine nucleotide translocase</article-title>. <source>Biochem. J.</source>
<volume>268</volume>, <fpage>153</fpage>&#x02013;<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1042/bj2680153</pub-id><pub-id pub-id-type="pmid">2160810</pub-id></mixed-citation></ref><ref id="BST-46-829C101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Mattiasson</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>M&#x000e5;nsson</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Keep</surname><given-names>M.F.</given-names></name>, <name name-style="western"><surname>Waldmeier</surname><given-names>P.</given-names></name><etal>et al.</etal></person-group> (<year>2004</year>) <article-title>The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria</article-title>. <source>J. Bioenerg. Biomembr.</source>
<volume>36</volume>, <fpage>407</fpage>&#x02013;<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1023/B:JOBB.0000041776.31885.45</pub-id><pub-id pub-id-type="pmid">15377880</pub-id></mixed-citation></ref><ref id="BST-46-829C102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiepolo</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Angelin</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Palma</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sabatelli</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Merlini</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Nicolosi</surname><given-names>L.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in <italic>Col6a1</italic><sup>&#x02212;/&#x02212;</sup> myopathic mice</article-title>. <source>Br. J. Pharmacol.</source>
<volume>157</volume>, <fpage>1045</fpage>&#x02013;<lpage>1052</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00316.x</pub-id><pub-id pub-id-type="pmid">19519726</pub-id></mixed-citation></ref><ref id="BST-46-829C103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaller</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Paradis</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ngoh</surname><given-names>G.A.</given-names></name>, <name name-style="western"><surname>Assaly</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Buisson</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Drouot</surname><given-names>C.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>333</volume>, <fpage>696</fpage>&#x02013;<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.110.167486</pub-id><pub-id pub-id-type="pmid">20215409</pub-id></mixed-citation></ref><ref id="BST-46-829C104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>&#x00160;ileikyte&#x002d9;</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Neuenswander</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Hedrick</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>T.D.Y.</given-names></name>, <name name-style="western"><surname>Aub&#x000e9;</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title><italic>N</italic>-Phenylbenzamides as potent inhibitors of the mitochondrial permeability transition pore</article-title>. <source>ChemMedChem</source>
<volume>11</volume>, <fpage>283</fpage>&#x02013;<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1002/cmdc.201500545</pub-id><pub-id pub-id-type="pmid">26693836</pub-id></mixed-citation></ref><ref id="BST-46-829C105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fancelli</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Abate</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Amici</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Ballarini</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cappa</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect <italic>in vivo</italic></article-title>. <source>J. Med. Chem.</source>
<volume>57</volume>, <fpage>5333</fpage>&#x02013;<lpage>5347</lpage>
<pub-id pub-id-type="doi">10.1021/jm500547c</pub-id><pub-id pub-id-type="pmid">24918261</pub-id></mixed-citation></ref><ref id="BST-46-829C106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briston</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Koglin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mistry</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hartopp</surname><given-names>N.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Identification of ER-000444793, a cyclophilin D-independent inhibitor of mitochondrial permeability transition, using a high-throughput screen in cryopreserved mitochondria</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>, <fpage>37798</fpage>
<pub-id pub-id-type="doi">10.1038/srep37798</pub-id><pub-id pub-id-type="pmid">27886240</pub-id></mixed-citation></ref><ref id="BST-46-829C107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Fancelli</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Niedzwiecki</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ballarini</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Plyte</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>8</volume>, <fpage>433</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00433</pub-id><pub-id pub-id-type="pmid">25565966</pub-id></mixed-citation></ref><ref id="BST-46-829C108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Gehrke</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Imai</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Ouyang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.-W.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>103</volume>, <fpage>10793</fpage>&#x02013;<lpage>10798</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0602493103</pub-id><pub-id pub-id-type="pmid">16818890</pub-id></mixed-citation></ref><ref id="BST-46-829C109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemasters</surname><given-names>J.J.</given-names></name></person-group> (<year>2005</year>) <article-title>Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging</article-title>. <source>Rejuvenation Res.</source>
<volume>8</volume>, <fpage>3</fpage>&#x02013;<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1089/rej.2005.8.3</pub-id><pub-id pub-id-type="pmid">15798367</pub-id></mixed-citation></ref><ref id="BST-46-829C110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narendra</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Suen</surname><given-names>D.-F.</given-names></name> and <name name-style="western"><surname>Youle</surname><given-names>R.J.</given-names></name></person-group> (<year>2008</year>) <article-title>Parkin is recruited selectively to impaired mitochondria and promotes their autophagy</article-title>. <source>J. Cell Biol.</source>
<volume>183</volume>, <fpage>795</fpage>&#x02013;<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200809125</pub-id><pub-id pub-id-type="pmid">19029340</pub-id></mixed-citation></ref><ref id="BST-46-829C111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarou</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Kane</surname><given-names>L.A.</given-names></name> and <name name-style="western"><surname>Youle</surname><given-names>R.J.</given-names></name></person-group> (<year>2012</year>) <article-title>Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin</article-title>. <source>Dev. Cell</source>
<volume>22</volume>, <fpage>320</fpage>&#x02013;<lpage>333</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2011.12.014</pub-id><pub-id pub-id-type="pmid">22280891</pub-id></mixed-citation></ref><ref id="BST-46-829C112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitada</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Asakawa</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hattori</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Matsumine</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yamamura</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Minoshima</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>1998</year>) <article-title>Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism</article-title>. <source>Nature</source>
<volume>392</volume>, <fpage>605</fpage>&#x02013;<lpage>608</lpage>
<pub-id pub-id-type="doi">10.1038/33416</pub-id><pub-id pub-id-type="pmid">9560156</pub-id></mixed-citation></ref><ref id="BST-46-829C113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>PINK1 suppresses &#x003b1;-synuclein-induced neuronal injury: a novel mechanism in protein phosphatase 2A activation</article-title>. <source>Oncotarget</source>
<volume>9</volume>, <fpage>37</fpage>&#x02013;<lpage>53</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.21554</pub-id><pub-id pub-id-type="pmid">29416594</pub-id></mixed-citation></ref><ref id="BST-46-829C114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Lue</surname><given-names>L.-F.</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>D.G.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease</article-title>. <source>Brain</source>
<volume>140</volume>, <fpage>3233</fpage>&#x02013;<lpage>3251</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awx258</pub-id><pub-id pub-id-type="pmid">29077793</pub-id></mixed-citation></ref><ref id="BST-46-829C115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Suo</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Parkin overexpression ameliorates hippocampal long-term potentiation and &#x003b2;-amyloid load in an Alzheimer's disease mouse model</article-title>. <source>Hum. Mol. Genet.</source>
<volume>23</volume>, <fpage>1056</fpage>&#x02013;<lpage>1072</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt501</pub-id><pub-id pub-id-type="pmid">24105468</pub-id></mixed-citation></ref><ref id="BST-46-829C116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Rebeck</surname><given-names>G.W.</given-names></name>, <name name-style="western"><surname>Querfurth</surname><given-names>H.W.</given-names></name> and <name name-style="western"><surname>Moussa</surname><given-names>C.E.-H.</given-names></name></person-group> (<year>2009</year>) <article-title>Parkin promotes intracellular A&#x003b2;1&#x02013;42 clearance</article-title>. <source>Hum. Mol. Genet.</source>
<volume>18</volume>, <fpage>3206</fpage>&#x02013;<lpage>3216</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp258</pub-id><pub-id pub-id-type="pmid">19483198</pub-id></mixed-citation></ref><ref id="BST-46-829C117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khandelwal</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Herman</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Hoe</surname><given-names>H.-S.</given-names></name>, <name name-style="western"><surname>Rebeck</surname><given-names>G.W.</given-names></name> and <name name-style="western"><surname>Moussa</surname><given-names>C.E.-H.</given-names></name></person-group> (<year>2011</year>) <article-title>Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated A&#x003b2; in AD models</article-title>. <source>Hum. Mol. Genet.</source>
<volume>20</volume>, <fpage>2091</fpage>&#x02013;<lpage>2102</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr091</pub-id><pub-id pub-id-type="pmid">21378096</pub-id></mixed-citation></ref><ref id="BST-46-829C118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonskaya</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Hebron</surname><given-names>M.L.</given-names></name>, <name name-style="western"><surname>Desforges</surname><given-names>N.M.</given-names></name>, <name name-style="western"><surname>Schachter</surname><given-names>J.B.</given-names></name> and <name name-style="western"><surname>Moussa</surname><given-names>C.E.-H.</given-names></name></person-group> (<year>2014</year>) <article-title>Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance</article-title>. <source>J. Mol. Med.</source>
<volume>92</volume>, <fpage>373</fpage>&#x02013;<lpage>386</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-013-1112-3</pub-id><pub-id pub-id-type="pmid">24337465</pub-id></mixed-citation></ref><ref id="BST-46-829C119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>J.-H.</given-names></name>, <name name-style="western"><surname>Karuppagounder</surname><given-names>S.S.</given-names></name>, <name name-style="western"><surname>Gadad</surname><given-names>B.S.</given-names></name>, <name name-style="western"><surname>Koleske</surname><given-names>A.J.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Phosphorylation by the c-Abl protein tyrosine kinase inhibits Parkin's ubiquitination and protective function</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>107</volume>, <fpage>16691</fpage>&#x02013;<lpage>16696</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1006083107</pub-id><pub-id pub-id-type="pmid">20823226</pub-id></mixed-citation></ref><ref id="BST-46-829C120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonskaya</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Hebron</surname><given-names>M.L.</given-names></name>, <name name-style="western"><surname>Desforges</surname><given-names>N.M.</given-names></name>, <name name-style="western"><surname>Franjie</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Moussa</surname><given-names>C.E.H.</given-names></name></person-group> (<year>2013</year>) <article-title>Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance</article-title>. <source>EMBO Mol. Med.</source>
<volume>5</volume>, <fpage>1247</fpage>&#x02013;<lpage>1262</lpage>
<pub-id pub-id-type="doi">10.1002/emmm.201302771</pub-id><pub-id pub-id-type="pmid">23737459</pub-id></mixed-citation></ref><ref id="BST-46-829C121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenqiang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lonskaya</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Hebron</surname><given-names>M.L.</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Olszewski</surname><given-names>R.T.</given-names></name>, <name name-style="western"><surname>Neale</surname><given-names>J.H.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice</article-title>. <source>Hum. Mol. Genet.</source>
<volume>23</volume>, <fpage>4960</fpage>&#x02013;<lpage>4969</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu211</pub-id><pub-id pub-id-type="pmid">24847002</pub-id></mixed-citation></ref><ref id="BST-46-829C122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bingol</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Tea</surname><given-names>J.S.</given-names></name>, <name name-style="western"><surname>Phu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Reichelt</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bakalarski</surname><given-names>C.E.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy</article-title>. <source>Nature</source>
<volume>510</volume>, <fpage>370</fpage>&#x02013;<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1038/nature13418</pub-id><pub-id pub-id-type="pmid">24896179</pub-id></mixed-citation></ref><ref id="BST-46-829C123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>C.N.</given-names></name>, <name name-style="western"><surname>Baughman</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Phu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Tea</surname><given-names>J.S.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Coons</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria</article-title>. <source>Nat. Cell Biol.</source>
<volume>17</volume>, <fpage>160</fpage>&#x02013;<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1038/ncb3097</pub-id><pub-id pub-id-type="pmid">25621951</pub-id></mixed-citation></ref><ref id="BST-46-829C124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Serricchio</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Jauregui</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shanbhag</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Stoltz</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Di Paolo</surname><given-names>C.T.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Deubiquitinating enzymes regulate PARK2-mediated mitophagy</article-title>. <source>Autophagy</source>
<volume>11</volume>, <fpage>595</fpage>&#x02013;<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1080/15548627.2015.1034408</pub-id><pub-id pub-id-type="pmid">25915564</pub-id></mixed-citation></ref><ref id="BST-46-829C125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornelissen</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Wauters</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Van Humbeeck</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Mandemakers</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Koentjoro</surname><given-names>B.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy</article-title>. <source>Hum. Mol. Genet.</source>
<volume>23</volume>, <fpage>5227</fpage>&#x02013;<lpage>5242</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu244</pub-id><pub-id pub-id-type="pmid">24852371</pub-id></mixed-citation></ref><ref id="BST-46-829C126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durcan</surname><given-names>T.M.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>M.Y.</given-names></name>, <name name-style="western"><surname>P&#x000e9;russe</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Dashti</surname><given-names>E.A.</given-names></name>, <name name-style="western"><surname>Aguileta</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>McLelland</surname><given-names>G.L.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin</article-title>. <source>EMBO J.</source>
<volume>33</volume>, <fpage>2473</fpage>&#x02013;<lpage>2491</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201489729</pub-id><pub-id pub-id-type="pmid">25216678</pub-id></mixed-citation></ref><ref id="BST-46-829C127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>N.</given-names></name> and <name name-style="western"><surname>Hirose</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>) <article-title>Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane</article-title>. <source>Mol. Biol. Cell</source>
<volume>19</volume>, <fpage>1903</fpage>&#x02013;<lpage>1911</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e07-11-1103</pub-id><pub-id pub-id-type="pmid">18287522</pub-id></mixed-citation></ref><ref id="BST-46-829C128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thobois</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>) <article-title>USP30: a new promising target for Parkinson's disease?</article-title>
<source>Mov. Disord.</source>
<volume>30</volume>, <fpage>340</fpage>
<pub-id pub-id-type="doi">10.1002/mds.26185</pub-id><pub-id pub-id-type="pmid">25702807</pub-id></mixed-citation></ref><ref id="BST-46-829C129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>D.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30</article-title>. <source>Cell Res.</source>
<volume>24</volume>, <fpage>482</fpage>&#x02013;<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2014.20</pub-id><pub-id pub-id-type="pmid">24513856</pub-id></mixed-citation></ref><ref id="BST-46-829C130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexopoulou</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Perrett</surname><given-names>R.M.</given-names></name>, <name name-style="western"><surname>Elschami</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hurry</surname><given-names>M.E.D.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.T.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Deubiquitinase Usp8 regulates &#x003b1;-synuclein clearance and modifies its toxicity in Lewy body disease</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>113</volume>, <fpage>E4688</fpage>&#x02013;<lpage>E4697</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1523597113</pub-id><pub-id pub-id-type="pmid">27444016</pub-id></mixed-citation></ref><ref id="BST-46-829C131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozzi</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Valtorta</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Tedeschi</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Galbusera</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Pastori</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Bigi</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2008</year>) <article-title>Study of subcellular localization and proteolysis of ataxin-3</article-title>. <source>Neurobiol. Dis.</source>
<volume>30</volume>, <fpage>190</fpage>&#x02013;<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2008.01.011</pub-id><pub-id pub-id-type="pmid">18353661</pub-id></mixed-citation></ref><ref id="BST-46-829C132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwickart</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lill</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ferrando</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>French</surname><given-names>D.M.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival</article-title>. <source>Nature</source>
<volume>463</volume>, <fpage>103</fpage>&#x02013;<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1038/nature08646</pub-id><pub-id pub-id-type="pmid">20023629</pub-id></mixed-citation></ref><ref id="BST-46-829C133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rott</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Szargel</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Haskin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bandopadhyay</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Shani</surname><given-names>V.</given-names></name><etal>et al.</etal></person-group> (<year>2011</year>) <article-title>&#x003b1;-Synuclein fate is determined by USP9X-regulated monoubiquitination</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>108</volume>, <fpage>18666</fpage>&#x02013;<lpage>18671</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1105725108</pub-id><pub-id pub-id-type="pmid">22065755</pub-id></mixed-citation></ref><ref id="BST-46-829C134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Manczak</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Calkins</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Truong</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>T.P.</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>A.P.</given-names></name><etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Mitochondria-targeted catalase reduces abnormal APP processing, amyloid &#x003b2; production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension</article-title>. <source>Hum. Mol. Genet.</source>
<volume>21</volume>, <fpage>2973</fpage>&#x02013;<lpage>2990</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds128</pub-id><pub-id pub-id-type="pmid">22492996</pub-id></mixed-citation></ref><ref id="BST-46-829C135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mastroeni</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Nolz</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Khdour</surname><given-names>O.M.</given-names></name>, <name name-style="western"><surname>Sekar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Delvaux</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Cuyugan</surname><given-names>L.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Oligomeric amyloid &#x003b2; preferentially targets neuronal and not glial mitochondrial-encoded mRNAs</article-title>. <source>Alzheimers Dement.</source>
<ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/pii/S1552526017338761">https://www.sciencedirect.com/science/article/pii/S1552526017338761</ext-link>
<pub-id pub-id-type="doi">10.1016/j.jalz.2017.12.005</pub-id></mixed-citation></ref><ref id="BST-46-829C136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamat</surname><given-names>C.D.</given-names></name>, <name name-style="western"><surname>Gadal</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mhatre</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>K.S.</given-names></name>, <name name-style="western"><surname>Pye</surname><given-names>Q.N.</given-names></name> and <name name-style="western"><surname>Hensley</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>) <article-title>Antioxidants in central nervous system diseases: preclinical promise and translational challenges</article-title>. <source>J. Alzheimers Dis.</source>
<volume>15</volume>, <fpage>473</fpage>&#x02013;<lpage>493</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2008-15314</pub-id><pub-id pub-id-type="pmid">18997301</pub-id></mixed-citation></ref><ref id="BST-46-829C137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelso</surname><given-names>G.F.</given-names></name>, <name name-style="western"><surname>Porteous</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Coulter</surname><given-names>C.V.</given-names></name>, <name name-style="western"><surname>Hughes</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Porteous</surname><given-names>W.K.</given-names></name>, <name name-style="western"><surname>Ledgerwood</surname><given-names>E.C.</given-names></name><etal>et al.</etal></person-group> (<year>2001</year>) <article-title>Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>4588</fpage>&#x02013;<lpage>4596</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M009093200</pub-id><pub-id pub-id-type="pmid">11092892</pub-id></mixed-citation></ref><ref id="BST-46-829C138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miquel</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Cassina</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mart&#x000ed;nez-Palma</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Souza</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Bolatto</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Rodr&#x000ed;guez-Bottero</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>70</volume>, <fpage>204</fpage>&#x02013;<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.02.019</pub-id><pub-id pub-id-type="pmid">24582549</pub-id></mixed-citation></ref><ref id="BST-46-829C139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McManus</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name> and <name name-style="western"><surname>Franklin</surname><given-names>J.L.</given-names></name></person-group> (<year>2011</year>) <article-title>The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease</article-title>. <source>J. Neurosci.</source>
<volume>31</volume>, <fpage>15703</fpage>&#x02013;<lpage>15715</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0552-11.2011</pub-id><pub-id pub-id-type="pmid">22049413</pub-id></mixed-citation></ref><ref id="BST-46-829C140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>L.F.</given-names></name>, <name name-style="western"><surname>Gruber</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cheah</surname><given-names>I.K.</given-names></name>, <name name-style="western"><surname>Goo</surname><given-names>C.K.</given-names></name>, <name name-style="western"><surname>Cheong</surname><given-names>W.F.</given-names></name>, <name name-style="western"><surname>Shui</surname><given-names>G.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic <italic>Caenorhabditis elegans</italic> model of Alzheimer disease</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>71</volume>, <fpage>390</fpage>&#x02013;<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.03.003</pub-id><pub-id pub-id-type="pmid">24637264</pub-id></mixed-citation></ref></ref-list></back></article>